# Title

 Food and Drugs. PART 202â€”PRESCRIPTION DRUG ADVERTISING


# ID

 CFR-2018-title21-vol4.Pt. 202


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Money       | [(125000.0, 'USD')]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Constraints | ['greater', 'maximum', 'more than', 'no later than', 'before', 'after', 'prior to', 'minimum', 'less than', 'at least', 'greater than', 'within', 'no less than', 'later than']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Duration    | ['6 month', '3.0 year', '2.0 year', '3.0 day', '1 year', '90.0 day', '30.0 hour', '60.0 day', '5.0 day', '1.0 year', '3 month', '30.0 day', '6.0 month', '2.0 day']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Condition   | ['subject to', 'until', 'if not', 'as soon as', 'where', 'provided that', 'when', 'not subject to', 'unless', 'if', 'unless and until']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Entities    | ['Federal', 'Distribution', 'Final', 'Master', 'Application', 'Portable', 'Calculation', 'Sterility', 'Verification', 'Acceptance', 'English', 'Material', 'Adequate', 'Rockville, MD', 'United States', 'Amphetamine', 'Sample', 'Trash', 'United States Pharmacopeia', 'Design', 'True', 'Exemption', 'Written', 'Serious', 'G112', 'Severe', 'Salvager', 'New', 'Examination', 'Work', 'Domestic', 'Spanish', 'Food', 'Suitable', 'Blood', 'Authorized', 'Manufacturing', 'Equipment', 'Minimum', 'Quality', 'Formula', 'Laboratory', 'Penicillin', 'Lot', 'Research', 'Experience', 'Risperidone', 'Expiration', 'Reserve', 'Pernicious', 'Specific', 'Request', 'Accelerated', 'Appropriate', 'Hexachlorophene', 'Drug', 'Maintenance', 'Dosage', 'Failure', 'Scope', 'Beltsville, MD', 'Solid', 'Salvage', 'Receipt', 'Establishment', 'Code', 'Stramonium', 'Input', 'U.S', 'Amyl', 'Organoleptic', 'Batch', 'Dates', 'Human', 'United States Pharmacopeial Convention, Inc', 'Sewage', 'Investigation', 'Relabel', 'Drugs', 'Access', 'Documentation', 'Training', 'Reminder', 'Pharmacy', 'Automatic', 'Wholesale', 'United States PharmacopeiaNational Formulary', 'Personnel', 'Process', 'Research and Testing', 'Strength', 'Such', 'Research, Office', 'Parenteral', 'Manufacture', 'Agriculture', 'Prior', 'Side', 'Ventilation', 'Labels', 'Fulfillment', 'Bulk', 'Areas', 'Avoid', 'Surveillance, Office', 'Columbia', 'Packaging', 'Homeopathic', 'Untrue', 'Puerto Rico', 'Purpose', 'Inactive', 'Sanitation', 'Fungicide', 'Plumbing', 'U.S. Pharmacopeial Convention, Inc', 'Actual', 'Misuse', 'Rm', 'Potable'] |
| Date        | ['2009-05-01', '2002-06-03', '1962-10-10', '1969-08-01', '1913-03-04', '1978-01-31', '2037-05-01', '2018-03-01', '1972-04-04', '1972-05-11', '1969-07-01', '2018-10-01', '1964-01-01', '1978-09-29', '1972-12-26', '1961-06-15', '1967-08-25', '1962-10-09', '2018-06-01', '2018-12-31', '1972-10-27', '2001-06-04', '1960-10-01', '1972-09-27']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |


# Structured Analysis With Context

 


## Money

| Money             | Context                                                                                                                                                                                                                                                                                                                                                                                             |
|:------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (125000.0, 'USD') | A person who provides information leading to the institution of a criminal proceeding against, and conviction of, a person for the sale, purchase, or trade of a drug sample, or the offer to sell, purchase, or trade a drug sample, in violation of section 503(c)(1) of the act, is entitled to one-half the criminal fine imposed and collected for such violation, but not more than $125,000. |


## Constraints

| Constraints   | Context                                                                                                                                    |
|:--------------|:-------------------------------------------------------------------------------------------------------------------------------------------|
| minimum       | against drug diversion by establishing procedures, requirements, and minimum standards for the distribution of prescription drugs and      |
| before        | set forth in paragraph (b) of this section, before the delivery of the drug sample; (2) The                                                |
| before        | a written request signed by the licensed practitioner before the delivery of the drug sample; (2) The                                      |
| at least      | drug samples by means of representatives shall conduct, at least annually, a complete and accurate physical inventory of                   |
| more than     | samples be delivered over a period of not more than 6 months, with the actual delivery dates for                                           |
| within        | requested forms, reports, records, or other required documents within 2 business days of a request by an                                   |
| within        | (1) Notify FDA, by telephone or in writing, within 5 working days; (2) Immediately initiate an investigation;                              |
| later than    | for and the results of the investigation, not later than 30 days after the date of the initial                                             |
| after         | of the investigation, not later than 30 days after the date of the initial notification in paragraph                                       |
| within        | (1) Notify FDA, by telephone or in writing, within 5 working days of becoming aware of a                                                   |
| later than    | for and the results of the investigation, not later than 30 days after the date of the initial                                             |
| after         | of the investigation, not later than 30 days after the date of the initial notification in paragraph                                       |
| within        | shall notify FDA, by telephone or in writing, within 30 days of becoming aware of the conviction                                           |
| later than    | provide FDA with a complete written report not later than 30 days after the date of the initial                                            |
| after         | complete written report not later than 30 days after  the date of the initial notification.                                                |
| within        | distributes drug samples shall inform FDA in writing within 30 days of selecting the individual responsible for                            |
| within        | sample is deemed to be a drug sample within  the meaning of the act.                                                                       |
| within        | sample is deemed to be a drug sample within  the meaning of the act.                                                                       |
| at least      | be retained by the recipient charitable institution for at least 3 years, containing the following information: (1) The                    |
| at least      | (g) Each recipient charitable institution shall conduct,  at least annually, an inventory of prescription drug sample stocks               |
| within        | (i) A charitable institution shall notify FDA  within 5 working days of becoming aware of a                                                |
| before        | prior sale, purchase, or trade of such drug. before                                                                                        |
| at least      | distribution of drug samples, shall retain them for at least  3 years after the date of their creation.                                    |
| after         | shall retain them for at least 3 years after  the date of their creation.                                                                  |
| within        | The records shall be made available  within  2 business days of a request.                                                                 |
| more than     | imposed and collected for such violation, but not more than  $125,000.                                                                     |
| minimum       | Prescription Drug Marketing Act of 1987 by providing minimum standards, terms, and conditions for the licensing by                         |
| before        | State licensing authority in accordance with this part before engaging in wholesale distributions of prescription drugs in                 |
| minimum       | Minimum required information for licensure. minimum                                                                                        |
| minimum       | The State licensing authority shall require the following minimum information from each wholesale drug distributor as part                 |
| more than     | a single license for a business entity operating more than one facility within that State, or for a                                        |
| within        | a business entity operating more than one facility within that State, or for a parent entity with                                          |
| within        | a business entity operating more than one facility within that State, or for a parent entity with                                          |
| more than     | a single license for a business entity operating more than one facility within that State, or for a                                        |
| minimum       | Minimum qualifications. minimum                                                                                                            |
| minimum       | The State licensing authority shall consider, at a minimum , the following factors in reviewing the qualifications                         |
| within        | who engage in wholesale distribution of prescription drugs within the State: (1) Any convictions of the applicant                          |
| minimum       | establishment and maintenance of prescription drug distribution records. minimum                                                           |
| minimum       | The State licensing law shall include the following  minimum requirements for the storage and handling of prescription                     |
| minimum       | outside the premises shall be kept to a minimum  and be well-controlled.                                                                   |
| after         | equipped with an alarm system to detect entry after  hours.                                                                                |
| before        | the drug has been held, stored, or shipped before or during its return and the condition of                                                |
| after         | agency officials for a period of 3 years after  the date of their creation.                                                                |
| within        | electronically retrievable shall be made available for inspection within 2 working days of a request by an                                 |
| after         | This documentation shall be maintained for 2 years  after  disposition of the outdated drugs.                                              |
| after         | that is cut into the dosage form surface after  it has been completed.                                                                     |
| after         | of the approved application will have 1 year after the date of an agency denial to imprint                                                 |
| within        | repacker, relabeler, salvager, private label distributor, or establishment within any State or Territory of the United States,             |
| after         | assigned to the establishment, as identified by FDA, after  the establishment registration required in this part.                          |
| at least      | form (e.g., tablet, capsule, or solution) that contains at least one active pharmaceutical ingredient, generally, but not necessarily,     |
| more than     | When operations are conducted at  more than one establishment and common ownership and control among                                       |
| no later than | (a) Registrants must register each domestic establishment  no later than 5 calendar days after beginning to manufacture, repack,           |
| after         | domestic establishment no later than 5 calendar days after beginning to manufacture, repack, relabel, or salvage a                         |
| before        | (b) Registrants must register each foreign establishment  before a drug or an animal feed bearing or                                       |
| no later than | Registrants must update their registration information  no later than 30 calendar days after: (1) Closing or selling                       |
| prior to      | of initial registration, if the initial registration occurs prior to  October 1.                                                           |
| within        | the information submitted under paragraph (c)(1)of this section within 30 calendar days after any change to that                           |
| after         | paragraph (c)(1)of this section within 30 calendar days after  any change to that information.                                             |
| before        | voluntarily reserve a proposed NDC for a drug, before the drug is listed, by submitting the following                                      |
| after         | for a drug when there is a change, after the drug is initially marketed, to any of                                                         |
| before        | was assigned to it as described in &#167;&#8201;207.33, before  marketing was discontinued.                                                |
| more than     | When operations are conducted at  more than one establishment, and common ownership and control exists                                     |
| after         | When,  after initial registration of an establishment, must drug listing                                                                   |
| no later than | initial registration, drug listing information must be submitted no later than 3 calendar days after the initial registration of           |
| after         | be submitted no later than 3 calendar days after  the initial registration of the establishment.                                           |
| within        | Such advertisements must be submitted  within  30 calendar days after FDA's request.                                                       |
| after         | advertisements must be submitted within 30 calendar days after  FDA's request.                                                             |
| within        | Such advertisements must be submitted  within  30 calendar days after our request.                                                         |
| after         | advertisements must be submitted within 30 calendar days after  our request.                                                               |
| before        | (a) The NDC assigned to the drug immediately  before the drug is received by the registrant for                                            |
| minimum       | must review and update listing information at a minimum , as follows: (a) Registrants must provide listing                                 |
| after         | been made since the previous annual registration update. after                                                                             |
| prior to      | every drug subject to listing under this part prior to commercial distribution and are encouraged to update listing                        |
| minimum       | content of labeling must be provided at a minimum  in the English language.                                                                |
| prior to      | granted a request for waiver of this requirement prior to the date on which submission of such information                                 |
| after         | obtained under &#167;&#8201;207.33, &#167;&#8201;207.49, &#167;&#8201;207.53, &#167;&#8201;207.54, or &#167;&#8201;207.57. after           |
| within        | this part, drug product also means biological product within the meaning of section 351(a) of the Public                                   |
| no less than  | Guide.&#8221; The established or proper name shall be no less than  one-half the height of the brand name.                                 |
| after         | recent revision of the Medication Guide placed immediately after  the last section.                                                        |
| before        | shall obtain FDA approval of the Medication Guide before  the Medication Guide may be distributed.                                         |
| minimum       | 225, and 226 of this chapter contain the minimum current good manufacturing practice for methods to be                                     |
| within        | is intended to have uniform character and quality, within specified limits, and is produced according to a                                 |
| at least      | Fiber means any particulate contaminant with a length at least  three times greater than its width.                                        |
| greater than  | contaminant with a length at least three times greater than  its width.                                                                    |
| after         | (6) Nonfiber releasing filter means any filter, which  after appropriate pretreatment such as washing or flushing, will                    |
| within        | of a batch, having uniform character and quality within specified limits; or, in the case of a                                             |
| within        | of a batch, having uniform character and quality within specified limits; or, in the case of a                                             |
| more than     | derived from a sheet of material on which more than  one item of labeling is printed.                                                      |
| minimum       | (a) The regulations in this part contain the  minimum current good manufacturing practice for preparation of drug                          |
| within        | human foods, and which products may also fall within the legal definition of drugs by virtue of                                            |
| within        | (c) Operations shall be performed  within  specifically defined areas of adequate size.                                                    |
| before        | testing, or examination by the quality control unit before release for manufacturing or packaging; (2) Holding rejected                    |
| before        | testing, or examination by the quality control unit before release for manufacturing or packaging; (2) Holding rejected                    |
| before        | (6) Packaging and labeling operations;                                                                                                     |
|               |                       (7) Quarantine storage  before release of drug products; (8) Storage of drug                                         |
| after         | of drug products; (8) Storage of drug products after release; (9) Control and laboratory operations; (10) Aseptic                          |
| prior to      | identification; (5) Protection of clean equipment from contamination prior to use; (6) Inspection of equipment for cleanliness immediately |
| before        | use; (6) Inspection of equipment for cleanliness immediately before  use.                                                                  |
| maximum       | is necessary, an additional nonfiber-releasing filter having a maximum nominal pore size rating of 0.2 micron (0.45                        |
| before        | (a) Upon receipt and  before acceptance, each container or grouping of containers of                                                       |
| within        | Storage  within the area shall conform to the requirements of                                                                              |
| at least      | identity of each component of a drug product. at least                                                                                     |
| at least      | from the supplier of a component, provided that at least one specific identity test is conducted on such                                   |
| at least      | may be accepted from the supplier, provided that at least a visual identification is conducted on such containers/closures                 |
| before        | intended use shall be subjected to microbiological tests before  use.                                                                      |
| after         | unit in accordance with &#167;&#8201;211.84 as necessary, e.g., after  storage for long periods or                                         |
| after         | unit in accordance with &#167;&#8201;211.84 as necessary, e.g., after  storage for long periods or                                         |
| within        | be attached to a medical gas supply system within a hospital, health care entity, nursing home, other                                      |
| less than     | be formulated with the intent to provide not less than 100 percent of the labeled or established amount                                    |
| after         | at commencement or completion of significant phases or after  storage for long periods.                                                    |
| before        | sampled, and examined or tested upon receipt and before use in packaging or labeling of a drug                                             |
| after         | a 100-percent examination for correct labeling during or after completion of finishing operations; or (3) Use of                           |
| after         | a 100-percent examination for correct labeling during or after completion of finishing operations; or (3) Use of                           |
| before        | packaging and labeling materials for suitability and correctness before packaging operations, and documentation of such examination in     |
| before        | Inspection of the packaging and labeling facilities immediately before use to assure that all drug products have                           |
| within        | the drug class, and a list of products within  that class.                                                                                 |
| before        | labeling required by this regulation may be made before FDA approval, as provided under &#167;&#8201;314.70(c) of this                     |
| at least      | bear dosage limitations and they are stable for at least  3 years as supported by appropriate stability data.                              |
| before        | They shall include:                                                                                                                        |
|               |                       (a) Quarantine of drug products  before  release by the quality control unit.                                        |
| within        | written specifications for the acceptance of each lot within each shipment of components, drug product containers, closures,               |
| prior to      | the identity and strength of each active ingredient, prior to  release.                                                                    |
| prior to      | of shortlived radiopharmaceuticals, such batches may be released prior to completion of sterility and/or pyrogen testing, provided such    |
| prior to      | appropriate standards, specifications, and any other relevant criteria. prior to                                                           |
| after         | (as directed in the labeling) as well as after  they are reconstituted.                                                                    |
| at least      | shall be a written assessment of stability based at least on testing or examination of the drug product                                    |
| at least      | The reserve sample consists of  at least twice the quantity necessary for all tests required                                               |
| after         | reserve sample shall be retained for 1 year after the expiration date of the last lot of                                                   |
| after         | sample shall be retained for: (i) Three months after the expiration date of the last lot of                                                |
| after         | sample shall be retained for: (i) Three months after the expiration date of the last lot of                                                |
| more than     | expiration dating period of the drug product is more than  30 days.                                                                        |
| after         | reserve sample shall be retained for 3 years after distribution of the last lot of the drug                                                |
| at least      | The reserve sample consists of  at least twice the quantity necessary to perform all the                                                   |
| at least      | by acceptable statistical procedures shall be examined visually at least once a year for evidence of deterioration unless                  |
| after         | reserve sample shall be retained for 1 year after  the expiration date of the drug product.                                                |
| after         | sample shall be retained for: (i) Three months after the expiration date of the drug product if                                            |
| after         | sample shall be retained for: (i) Three months after the expiration date of the drug product if                                            |
| more than     | expiration dating period of the drug product is more than  30 days.                                                                        |
| after         | reserve sample must be retained for 3 years after the lot or batch of drug product is                                                      |
| at least      | of a drug product shall be retained for at least 1 year after the expiration date of the                                                   |
| after         | shall be retained for at least 1 year after the expiration date of the batch or, in                                                        |
| after         | shall be retained for at least 1 year after the expiration date of the batch or, in                                                        |
| at least      | components, drug product containers, closures, and labeling for at least 1 year after the expiration date or, in                           |
| after         | closures, and labeling for at least 1 year after the expiration date or, in the case of                                                    |
| after         | closures, and labeling for at least 1 year after the expiration date or, in the case of                                                    |
| at least      | that data therein can be used for evaluating, at least annually, the quality standards of each drug product                                |
| maximum       | (7) A statement of theoretical yield, including the maximum and minimum percentages of theoretical yield beyond which                      |
| minimum       | statement of theoretical yield, including the maximum and minimum percentages of theoretical yield beyond which investigation according    |
| before        | (6) Inspection of the packaging and labeling area before and after use; (7) A statement of the                                             |
| after         | of the packaging and labeling area before and after use; (7) A statement of the actual yield                                               |
| before        | determine compliance with all established, approved written procedures before  a batch is released or distributed.                         |
| maximum       | (including a percentage of theoretical yield exceeding the maximum or minimum percentages established in master production and             |
| minimum       | percentage of theoretical yield exceeding the maximum or minimum percentages established in master production and control records)         |
| at least      | verify that the modification produced results that are at least as accurate and reliable for the material being                            |
| at least      | involving a drug product shall be maintained until at least 1 year after the expiration date of the                                        |
| after         | shall be maintained until at least 1 year after the expiration date of the drug product, or                                                |
| after         | shall be maintained until at least 1 year after the expiration date of the drug product, or                                                |
| after         | written records shall be maintained for 3 years after  distribution of the drug product.                                                   |
| before        | drug products have been held, stored, or shipped before or during their return, or if the condition                                        |
| within        | drug intended to have uniform character and quality, within specified limits, that is produced according to a                              |
| prior to      | Conditional final release means a final release made  prior to completion of a required finished-product test because of                   |
| within        | of a batch, having uniform character and quality within  specified limits.                                                                 |
| within        | that ensures its having uniform character and quality within  specified limits.                                                            |
| within        | of PET drug having uniform character and quality, within specified limits, that is produced during one succession                          |
| minimum       | good manufacturing practice for PET drugs is the minimum requirements for the methods to be used in,                                       |
| before        | You must approve or reject,  before implementation, any initial specifications, methods, processes, or procedures,                         |
| before        | the components used to make the inactive ingredient before  the components are released for use.                                           |
| at least      | You must perform  at least a visual identification of each lot of containers                                                               |
| minimum       | of action limits on radiochemical yield, i.e., the minimum percentage of yield beyond which investigation and corrective                   |
| before        | be checked to ensure cleanliness and suitability immediately before  use.                                                                  |
| before        | accuracy, sensitivity, specificity, and reproducibility of the procedure. before                                                           |
| before        | drug product conforms to specifications, except for sterility. before                                                                      |
| before        | For a PET drug product produced in sub-batches,  before final release, you must conduct an appropriate laboratory                          |
| before        | Sterility testing need not be completed  before final release but must be started within 30                                                |
| within        | completed before final release but must be started within  30 hours after completion of production.                                        |
| after         | release but must be started within 30 hours after  completion of production.                                                               |
| within        | been obtained if the test had been started within  the 30-hour time period.                                                                |
| after         | complete the omitted test using the reserve sample after the malfunction is corrected, and document that reasonable                        |
| before        | product must conform to specifications, except for sterility, before  final release.                                                       |
| at least      | referenced in this part for a period of at least 1 year from the date of final release,                                                    |
| within        | medicated feed shall be deemed to be adulterated within the meaning of section 501(a)(2)(B) of the act,                                    |
| within        | medicated feed shall be deemed to be adulterated within the meaning of section 501(a)(2)(B) of the act,                                    |
| at least      | shall be tested for accuracy upon installation and at least once a year thereafter, or more frequently as                                  |
| after         | installation and at least once a year there after , or more frequently as may be necessary                                                 |
| at least      | number or the feed manufacturer's shipment identification number at least  the following information:                                      |
| at least      | section shall be maintained on the premises for at least one year after complete use of a drug                                             |
| after         | on the premises for at least one year after complete use of a drug component of a                                                          |
| at least      | (Form FDA 3448) for their manufacture and marketing, at least three representative samples of medicated feed containing each               |
| at least      | performed on the first batch using the drug. at least                                                                                      |
| less than     | on the premises for a period of not less than  1 year after distribution of the medicated feed.                                            |
| after         | a period of not less than 1 year after  distribution of the medicated feed.                                                                |
| within        | in accord with label specifications or is not within permissible assay limits as specified in this chapter,                                |
| after         | a responsible individual, and kept for 1 year after all the labels from that batch have been                                               |
| less than     | qualified person and shall be retained for not less than 1 year after production of the last batch                                         |
| after         | be retained for not less than 1 year after production of the last batch or production run                                                  |
| at least      | The Master Record File or card shall include  at least the following: (i) The name of the medicated                                        |
| less than     | shall be retained on the premises for not less than  1 year.                                                                               |
| at least      | The production record shall include  at least the following: (i) Product identification, date of production,                               |
| less than     | shall be retained on the premises for not less than one year after the date of shipment of                                                 |
| after         | the premises for not less than one year after  the date of shipment of the medicated feed.                                                 |
| before        | the raw materials and Type A medicated article(s) before , during, and after production.                                                   |
| after         | and Type A medicated article(s) before, during, and after  production.                                                                     |
| within        | component(s) with the first five consecutive batches assaying within the limitations, followed thereafter by assay of representative       |
| less than     | thereafter by assay of representative samples of not less than  5 percent of all batches produced.                                         |
| within        | When any batch does not assay  within limitations, each batch should again be assayed until                                                |
| within        | When any batch does not assay  within limitations, each batch should again be assayed until                                                |
| at least      | and shall be maintained for a period of at least 2 years after distribution by the manufacturer of                                         |
| after         | for a period of at least 2 years after distribution by the manufacturer of the Type A                                                      |
| at least      | medicated article(s) produced and shall be retained for at least 2 years after distribution by the manufacturer has                        |
| after         | shall be retained for at least 2 years after  distribution by the manufacturer has been completed.                                         |
| at least      | Such records shall be retained for  at least 2 years after the date of the shipment                                                        |
| after         | shall be retained for at least 2 years after the date of the shipment by the manufacturer                                                  |
| within        | to established hypothyroidism are regarded as new drugs within the meaning of section 201(p) of the Federal                                |
| after         | dispensing of stramonium preparations contrary to this statement after 60 days following the date of its publication                       |
| within        | regarded as misbranded unless the labeling on or within the package from which the drug is to                                              |
| after         | this statement of policy if such act occurs after  July 1, 1969.                                                                           |
| after         | the post coronary state, except angina pectoris present after  coronary occlusion and myocardial infarction.                               |
| before        | new drug that requires an approved new-drug application before  marketing.                                                                 |
| more than     | use in self-medication are aqueous solutions containing not more than  0.04 percent potassium permanganate.                                |
| prior to      | be regarded as misbranded if at any time prior to dispensing the label fails to bear the statement                                         |
| more than     | for veterinary use if such drug contains not more than 50 percent of potassium permanganate and includes other                             |
| more than     | (i) It is an aqueous solution containing not more than  0.04 percent potassium permanganate.                                               |
| within        | any potassium permanganate preparations intended for drug use within the jurisdiction of the Federal Food, Drug, and                       |
| after         | Drug, and Cosmetic Act contrary to this statement after 60 days from the date of its publication                                           |
| within        | for the availability of such oral preparations, standardized within the meaning of the broad limits characteristic of                      |
| within        | intrinsic factor concentrate will be regarded as misbranded within the meaning of section 503(b) of the Federal                            |
| within        | intrinsic factor concentrate will be regarded as adulterated within  the meaning of section 402(a)(2)(C) of the act.                       |
| within        | be initiated with respect to any article shipped within the jurisdiction of the act contrary to the                                        |
| after         | contrary to the provisions of this policy statement after the 180th day following publication of this statement                            |
| within        | statement &#8220;Rx only,&#8221; and the labeling on or within the package from which the drug is to                                       |
| within        | that products containing hexachlorophene may appropriately be used within  clearly delineated conditions of use.                           |
| after         | first, if all the following conditions were met after September 27, 1972: (i) The product is labeled                                       |
| within        | for the revised label and full disclosure labeling. within                                                                                 |
| within        | formulation where appropriate to comply with this order. within                                                                            |
| within        | a part of the new drug application file. within                                                                                            |
| within        | obtained from use of the drug as recommended. within                                                                                       |
| within        | approved new drug application, which must be submitted within the time set out in paragraph (c)(4) of                                      |
| prior to      | such ingredients, shall be adequately tested for safety prior to  marketing.                                                               |
| prior to      | or product whose safety is not adequately substantiated prior to marketing may be adulterated and will in any                              |
| within        | Shipments of products falling  within the scope of paragraphs (c), (d), or (e)                                                             |
| after         | herein shall be the subject of regulatory proceedings after  the effective date of the final order.                                        |
| more than     | to a compound, mixture, or preparation containing not more than 200 milligrams of codeine per 100 milliliters or                           |
| prior to      | be presented to the person dispensing the substance, prior to  the dispensing.                                                             |
| greater than  | a manner that creates an impression of value greater than  their true functional role in the formulation.                                  |
| at least      | running text, the established name shall be used at least once in the running text in association with                                     |
| at least      | running text, the established name shall be used at least once in the running text in association with                                     |
| at least      | running text, the established name shall be used at least once in the running text in association with                                     |
| at least      | the column, the established name shall be used at least once in such column of running text in                                             |
| at least      | the column, the established name shall be used at least once in such column of running text in                                             |
| at least      | the column, the established name shall be used at least once in such column of running text in                                             |
| at least      | name shall be printed in letters that are at least half as large as the letters comprising the                                             |
| more than     | to a combination of active ingredients present in more than one preparation (the individual preparations differing from each               |
| at least      | The advertisement shall prominently display the name of at least one specific dosage form and shall have the                               |
| after         | approved pursuant to section 505 of the act after October 10, 1962, or a prescription drug covered                                         |
| after         | approved pursuant to section 505 of the act after October 10, 1962, or a prescription drug covered                                         |
| prior to      | application or a supplement thereto that became effective prior to October 10, 1962, an advertisement may recommend or                     |
| greater       | the information relating to effectiveness is presented in greater scope, depth, or detail than is required by                              |
| greater       | category of drugs, or that it has a greater potency per unit of weight, in a way                                                           |
| more than     | on another full page) of an advertisement on more than one page, information relating to side effects and                                  |
| after         | in his absence the officer acting as Commissioner), after evaluating the reliability of such information, has notified                     |
| within        | the drug; and (iii) The sponsor has failed within a reasonable time as specified in such notification                                      |
| within        | advertisements for the drug is no longer necessary. within                                                                                 |
| after         | (2) Within a reasonable time  after information concerning the possibility that a drug may                                                 |
| prior to      | be submitted to the Food and Drug Administration prior to  publication for comment.                                                        |
| before        | will be given a reasonable time for correction before  any regulatory action is taken under this section.                                  |
| before        | shall have an opportunity for a regulatory hearing before the Food and Drug Administration pursuant to part                                |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 6.0 month  | An arrangement by which a licensed practitioner requests in writing that a specified number of drug samples be delivered over a period of not more than 6 months, with the actual delivery dates for parts of the order to be set by subsequent oral communication or electronic transmission, is not considered to be a standing request.                                                                                                             |
| 2.0 day    | A manufacturer or authorized distributor of record that contracts with a third party to maintain some or all of its records shall produce requested forms, reports, records, or other required documents within 2 business days of a request by an authorized representative of FDA or another Federal, State, or local regulatory or law enforcement official.                                                                                        |
| 30.0 day   | A manufacturer or authorized distributor of record that has reason to believe that any person has falsified drug sample requests, receipts, or records, or is diverting drug samples, shall:                                                                                                                                                                                                                                                           |
|            |                       (1) Notify FDA, by telephone or in writing, within 5 working days;                                                                                                                                                                                                                                                                                                                                                               |
|            |                       (2) Immediately initiate an investigation; and                                                                                                                                                                                                                                                                                                                                                                                   |
|            |                       (3) Provide FDA with a complete written report, including the reason for and the results of the investigation, not later than 30 days after the date of the initial notification in paragraph (a)(1) of this section.                                                                                                                                                                                                            |
| 30.0 day   | (3) Provide FDA with a complete written report, including the reason for and the results of the investigation, not later than 30 days after the date of the initial notification in paragraph (b)(1) of this section.                                                                                                                                                                                                                                  |
| 30.0 day   | (1) A manufacturer or authorized distributor of record that distributes drug samples shall notify FDA, by telephone or in writing, within 30 days of becoming aware of the conviction of one or more of its representatives for a violation of section 503(c)(1) of the act or any State law involving the sale, purchase, or trade of a drug sample or the offer to sell, purchase, or trade a drug sample.                                           |
| 30.0 day   | (2) A manufacturer or authorized distributor of record shall provide FDA with a complete written report not later than 30 days after the date of the initial notification.                                                                                                                                                                                                                                                                             |
| 30.0 day   | A manufacturer or authorized distributor of record that distributes drug samples shall inform FDA in writing within 30 days of selecting the individual responsible for responding to a request for information about drug samples of that individual's name, business address, and telephone number.                                                                                                                                                  |
| 3.0 year   | (e) The recipient charitable institution shall prepare at the time of collection or delivery of a drug sample a complete and accurate donation record, a copy of which shall be retained by the recipient charitable institution for at least 3 years, containing the following information:                                                                                                                                                           |
|            |                       (1) The name, address, and telephone number of the licensed practitioner (or donating charitable institution);                                                                                                                                                                                                                                                                                                                   |
|            |                       (2) The manufacturer, brand name, quantity, and lot or control number of the drug sample donated; and                                                                                                                                                                                                                                                                                                                            |
|            |                       (3) The date of the donation.                                                                                                                                                                                                                                                                                                                                                                                                    |
| 3.0 year   | (b) The drug origin statement is subject to the record retention requirements of &#167;&#8201;203.60 and must be retained by all wholesale distributors involved in the distribution of the drug product, whether authorized or unauthorized, for 3 years.                                                                                                                                                                                             |
| 3.0 year   | Any person required to create or maintain reports, lists, or other records under PDMA, PDA, or this part, including records relating to the distribution of drug samples, shall retain them for at least 3 years after the date of their creation.                                                                                                                                                                                                     |
| 2.0 day    | The records shall be made available within 2 business days of a request.                                                                                                                                                                                                                                                                                                                                                                               |
| 3.0 year   | (2) Inventories and records shall be made available for inspection and photocopying by authorized Federal, State, or local law enforcement agency officials for a period of 3 years after the date of their creation.                                                                                                                                                                                                                                  |
| 2.0 year   | This documentation shall be maintained for 2 years after disposition of the outdated drugs.                                                                                                                                                                                                                                                                                                                                                            |
| 1.0 year   | If FDA denies the request, the holder of the approved application will have 1 year after the date of an agency denial to imprint the drug product.                                                                                                                                                                                                                                                                                                     |
| 5.0 day    | (a) Registrants must register each domestic establishment no later than 5 calendar days after beginning to manufacture, repack, relabel, or salvage a drug or an animal feed bearing or containing a new animal drug at such establishment.                                                                                                                                                                                                            |
| 30.0 day   | Registrants must update their registration information no later than 30 calendar days after:                                                                                                                                                                                                                                                                                                                                                           |
|            |                       (1) Closing or selling an establishment;                                                                                                                                                                                                                                                                                                                                                                                         |
|            |                       (2) Changing an establishment's name or physical address; or                                                                                                                                                                                                                                                                                                                                                                     |
|            |                       (3) Changing the name, mailing address, telephone number, or email address of the official contact or the United States agent.                                                                                                                                                                                                                                                                                                   |
| 30.0 day   | (2) Each person who is assigned an NDC labeler code must update the information submitted under paragraph (c)(1)of this section within 30 calendar days after any change to that information.                                                                                                                                                                                                                                                          |
| 2.0 year   | (4) If the required information is submitted and the proposed NDC is properly formatted and not already assigned or reserved, FDA will reserve the proposed NDC for a period of 2 years from the date of submission.                                                                                                                                                                                                                                   |
| 2.0 year   | If the drug for which the proposed NDC is reserved is not listed in accordance with &#167;&#8201;207.49 or &#167;&#8201;207.53 during such 2-year period, the reservation of the proposed NDC will lapse.                                                                                                                                                                                                                                              |
| 3.0 day    | For each drug being manufactured, repacked, relabeled, or salvaged for commercial distribution at an establishment at the time of initial registration, drug listing information must be submitted no later than 3 calendar days after the initial registration of the establishment.                                                                                                                                                                  |
| 30.0 day   | Such advertisements must be submitted within 30 calendar days after FDA's request.                                                                                                                                                                                                                                                                                                                                                                     |
| 30.0 day   | Such advertisements must be submitted within 30 calendar days after our request.                                                                                                                                                                                                                                                                                                                                                                       |
| 3.0 year   | (h) Pending consideration of a proposed exemption, published in the Federal Register of September 29, 1978, the requirements in this section shall not be enforced for human OTC drug products if their labeling does not bear dosage limitations and they are stable for at least 3 years as supported by appropriate stability data.                                                                                                                 |
| 1.0 year   | The retention time is as follows:                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |                       (1) For an active ingredient in a drug product other than those described in paragraphs (a) (2) and (3) of this section, the reserve sample shall be retained for 1 year after the expiration date of the last lot of the drug product containing the active ingredient.                                                                                                                                                         |
| 3 month    | (2) For an active ingredient in a radioactive drug product, except for nonradioactive reagent kits, the reserve sample shall be retained for:                                                                                                                                                                                                                                                                                                          |
|            |                       (i) Three months after the expiration date of the last lot of the drug product containing the active ingredient if the expiration dating period of the drug product is 30 days or less; or                                                                                                                                                                                                                                       |
|            |                       (ii) Six months after the expiration date of the last lot of the drug product containing the active ingredient if the expiration dating period of the drug product is more than 30 days.                                                                                                                                                                                                                                         |
| 30.0 day   | (2) For an active ingredient in a radioactive drug product, except for nonradioactive reagent kits, the reserve sample shall be retained for:                                                                                                                                                                                                                                                                                                          |
|            |                       (i) Three months after the expiration date of the last lot of the drug product containing the active ingredient if the expiration dating period of the drug product is 30 days or less; or                                                                                                                                                                                                                                       |
|            |                       (ii) Six months after the expiration date of the last lot of the drug product containing the active ingredient if the expiration dating period of the drug product is more than 30 days.                                                                                                                                                                                                                                         |
| 6 month    | (2) For an active ingredient in a radioactive drug product, except for nonradioactive reagent kits, the reserve sample shall be retained for:                                                                                                                                                                                                                                                                                                          |
|            |                       (i) Three months after the expiration date of the last lot of the drug product containing the active ingredient if the expiration dating period of the drug product is 30 days or less; or                                                                                                                                                                                                                                       |
|            |                       (ii) Six months after the expiration date of the last lot of the drug product containing the active ingredient if the expiration dating period of the drug product is more than 30 days.                                                                                                                                                                                                                                         |
| 30.0 day   | (2) For an active ingredient in a radioactive drug product, except for nonradioactive reagent kits, the reserve sample shall be retained for:                                                                                                                                                                                                                                                                                                          |
|            |                       (i) Three months after the expiration date of the last lot of the drug product containing the active ingredient if the expiration dating period of the drug product is 30 days or less; or                                                                                                                                                                                                                                       |
|            |                       (ii) Six months after the expiration date of the last lot of the drug product containing the active ingredient if the expiration dating period of the drug product is more than 30 days.                                                                                                                                                                                                                                         |
| 3.0 year   | (3) For an active ingredient in an OTC drug product that is exempt from bearing an expiration date under &#167;&#8201;211.137, the reserve sample shall be retained for 3 years after distribution of the last lot of the drug product containing the active ingredient.                                                                                                                                                                               |
| 1.0 year   | The retention time is as follows:                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |                       (1) For a drug product other than those described in paragraphs (b) (2) and (3) of this section, the reserve sample shall be retained for 1 year after the expiration date of the drug product.                                                                                                                                                                                                                                  |
| 3 month    | (2) For a radioactive drug product, except for nonradioactive reagent kits, the reserve sample shall be retained for:                                                                                                                                                                                                                                                                                                                                  |
|            |                       (i) Three months after the expiration date of the drug product if the expiration dating period of the drug product is 30 days or less; or                                                                                                                                                                                                                                                                                        |
|            |                       (ii) Six months after the expiration date of the drug product if the expiration dating period of the drug product is more than 30 days.                                                                                                                                                                                                                                                                                          |
| 30.0 day   | (2) For a radioactive drug product, except for nonradioactive reagent kits, the reserve sample shall be retained for:                                                                                                                                                                                                                                                                                                                                  |
|            |                       (i) Three months after the expiration date of the drug product if the expiration dating period of the drug product is 30 days or less; or                                                                                                                                                                                                                                                                                        |
|            |                       (ii) Six months after the expiration date of the drug product if the expiration dating period of the drug product is more than 30 days.                                                                                                                                                                                                                                                                                          |
| 6 month    | (2) For a radioactive drug product, except for nonradioactive reagent kits, the reserve sample shall be retained for:                                                                                                                                                                                                                                                                                                                                  |
|            |                       (i) Three months after the expiration date of the drug product if the expiration dating period of the drug product is 30 days or less; or                                                                                                                                                                                                                                                                                        |
|            |                       (ii) Six months after the expiration date of the drug product if the expiration dating period of the drug product is more than 30 days.                                                                                                                                                                                                                                                                                          |
| 30.0 day   | (2) For a radioactive drug product, except for nonradioactive reagent kits, the reserve sample shall be retained for:                                                                                                                                                                                                                                                                                                                                  |
|            |                       (i) Three months after the expiration date of the drug product if the expiration dating period of the drug product is 30 days or less; or                                                                                                                                                                                                                                                                                        |
|            |                       (ii) Six months after the expiration date of the drug product if the expiration dating period of the drug product is more than 30 days.                                                                                                                                                                                                                                                                                          |
| 3.0 year   | (3) For an OTC drug product that is exempt for bearing an expiration date under &#167;&#8201;211.137, the reserve sample must be retained for 3 years after the lot or batch of drug product is distributed.                                                                                                                                                                                                                                           |
| 1.0 year   | (a) Any production, control, or distribution record that is required to be maintained in compliance with this part and is specifically associated with a batch of a drug product shall be retained for at least 1 year after the expiration date of the batch or, in the case of certain OTC drug products lacking expiration dating because they meet the criteria for exemption under &#167;&#8201;211.137, 3 years after distribution of the batch. |
| 3.0 year   | (a) Any production, control, or distribution record that is required to be maintained in compliance with this part and is specifically associated with a batch of a drug product shall be retained for at least 1 year after the expiration date of the batch or, in the case of certain OTC drug products lacking expiration dating because they meet the criteria for exemption under &#167;&#8201;211.137, 3 years after distribution of the batch. |
| 1.0 year   | (b) Records shall be maintained for all components, drug product containers, closures, and labeling for at least 1 year after the expiration date or, in the case of certain OTC drug products lacking expiration dating because they meet the criteria for exemption under &#167;&#8201;211.137, 3 years after distribution of the last lot of drug product incorporating the component or using the container, closure, or labeling.                 |
| 3.0 year   | (b) Records shall be maintained for all components, drug product containers, closures, and labeling for at least 1 year after the expiration date or, in the case of certain OTC drug products lacking expiration dating because they meet the criteria for exemption under &#167;&#8201;211.137, 3 years after distribution of the last lot of drug product incorporating the component or using the container, closure, or labeling.                 |
| 1.0 year   | Written records involving a drug product shall be maintained until at least 1 year after the expiration date of the drug product, or 1 year after the date that the complaint was received, whichever is longer.                                                                                                                                                                                                                                       |
| 1.0 year   | Written records involving a drug product shall be maintained until at least 1 year after the expiration date of the drug product, or 1 year after the date that the complaint was received, whichever is longer.                                                                                                                                                                                                                                       |
| 3.0 year   | In the case of certain OTC drug products lacking expiration dating because they meet the criteria for exemption under &#167;&#8201;211.137, such written records shall be maintained for 3 years after distribution of the drug product.                                                                                                                                                                                                               |
| 30.0 hour  | Sterility testing need not be completed before final release but must be started within 30 hours after completion of production.                                                                                                                                                                                                                                                                                                                       |
| 30.0 hour  | The 30-hour requirement may be exceeded due to a weekend or holiday.                                                                                                                                                                                                                                                                                                                                                                                   |
| 30.0 hour  | If the sample for sterility testing is held longer than 30 hours, you must demonstrate that the longer period does not adversely affect the sample and the test results obtained will be equivalent to test results that would have been obtained if the test had been started within the 30-hour time period.                                                                                                                                         |
| 30.0 hour  | If the sample for sterility testing is held longer than 30 hours, you must demonstrate that the longer period does not adversely affect the sample and the test results obtained will be equivalent to test results that would have been obtained if the test had been started within the 30-hour time period.                                                                                                                                         |
| 1.0 year   | You must maintain all records and documentation referenced in this part for a period of at least 1 year from the date of final release, including conditional final release, of a PET drug product.                                                                                                                                                                                                                                                    |
| 1 year     | (8) All records required by this section shall be maintained on the premises for at least one year after complete use of a drug component of a specific lot number or feed manufacturer's shipment identification number.                                                                                                                                                                                                                              |
| 1.0 year   | (2) [Reserved]                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |                       (c) The originals or copies of all results of assays, including those from State feed control officials and any other governmental agency, shall be maintained on the premises for a period of not less than 1 year after distribution of the medicated feed.                                                                                                                                                                    |
| 1.0 year   | The proofread label shall be dated, initialed by a responsible individual, and kept for 1 year after all the labels from that batch have been used.                                                                                                                                                                                                                                                                                                    |
| 1.0 year   | (b) The Master Record File and production records shall comply with the following provisions:                                                                                                                                                                                                                                                                                                                                                          |
|            |                       (1) A Master Record File shall be prepared, checked, dated, and signed or initialed by a qualified person and shall be retained for not less than 1 year after production of the last batch or production run of medicated feed to which it pertains.                                                                                                                                                                            |
| 1.0 year   | (2) The original production record or copy thereof shall be prepared by qualified personnel for each batch or run of medicated feed produced and shall be retained on the premises for not less than 1 year.                                                                                                                                                                                                                                           |
| 1 year     | (2) The originals or copies of the distribution records shall be retained on the premises for not less than one year after the date of shipment of the medicated feed.                                                                                                                                                                                                                                                                                 |
| 1.0 year   | Where the results of laboratory assays of drug components, including assays by State feed control officials, indicate that the medicated feed is not in accord with the permissible limits specified in this chapter, investigation and corrective action shall be implemented immediately by the firm and such records shall be maintained on the premises for a period of 1 year.                                                                    |
| 1.0 year   | Such records shall be retained on the premises for 1 year following the date of last distribution.                                                                                                                                                                                                                                                                                                                                                     |
| 2.0 year   | Appropriate receipt and inventory records shall be maintained for 2 years, and such records shall show the origin of any drug components, the manufacturer's control number (if any), the dates and batches in which they were used, and the results of any testing of them.                                                                                                                                                                           |
| 2.0 year   | Such records shall be retained in the possession of the manufacturer and shall be maintained for a period of at least 2 years after distribution by the manufacturer of the Type A medicated article(s) has been completed.                                                                                                                                                                                                                            |
| 2.0 year   | (b) A separate batch-production and control record shall be prepared for each batch or run of Type A medicated article(s) produced and shall be retained for at least 2 years after distribution by the manufacturer has been completed.                                                                                                                                                                                                               |
| 2.0 year   | Such records shall be retained for at least 2 years after the date of the shipment by the manufacturer and shall include the name and address of the consignee, the date and quantity shipped, and the manufacturing dates, control numbers, or marks identifying the Type A medicated article(s) shipped.                                                                                                                                             |
| 2.0 year   | Records shall be maintained for a period of 2 years of all written or verbal complaints concerning the safety or efficacy of each Type A medicated article(s).                                                                                                                                                                                                                                                                                         |
| 60.0 day   | (d) The labeling or dispensing of stramonium preparations contrary to this statement after 60 days following the date of its publication in the Federal Register may be made the subject of regulatory proceedings.                                                                                                                                                                                                                                    |
| 60.0 day   | (d) The labeling or dispensing of any potassium permanganate preparations intended for drug use within the jurisdiction of the Federal Food, Drug, and Cosmetic Act contrary to this statement after 60 days from the date of its publication in the Federal Register may be made the subject of regulatory proceedings.                                                                                                                               |
| 30.0 day   | (ii) Within 30 days, or by (10-27-72) the holder of an approved new drug application submits a supplement to provide for the revised label and full disclosure labeling.                                                                                                                                                                                                                                                                               |
| 30.0 day   | (iii) Within 30 days, or by (10-27-72) the holder of an approved new drug application submits a supplement to provide for a revised formulation where appropriate to comply with this order.                                                                                                                                                                                                                                                           |
| 90.0 day   | (iv) Within 90 days, or by (12-26-72) the holder of an approved new drug application submits a supplement containing blood level data obtained from use of the drug as recommended, unless such information is a part of the new drug application file.                                                                                                                                                                                                |
| 90.0 day   | (v) Within 90 days, or by (12-26-72), the manufacturer or distributor of such a drug for which a new drug approval is not in effect submits a new drug application in accord with &#167;&#8201;314.50 of the new drug regulations (21 CFR 314.50), including blood level data obtained from use of the drug as recommended.                                                                                                                            |


## Condition

| Condition        | Context                                                                                                                                                          |
|:-----------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| when             | more effective than another drug in some particular when the difference has not been demonstrated by substantial                                                 |
| unless           | a quantitative statement of safety or effectiveness (a) unless the representation has been approved as part of                                                   |
| if               | new drug application or biologic license, or (b) if the drug is not a new drug or                                                                                |
| unless           | a quantitative statement of safety or effectiveness (a) unless the representation has been approved as part of                                                   |
| unless           | a quantitative statement of safety or effectiveness (a) unless the representation has been approved as part of                                                   |
| if               | in vitro, that the studies have clinical sign if icance,                                                                                                         |
| if               | vitro data may be included in the advertisement, if data are immediately preceded by the statement &#8220;The                                                    |
| unless           | &#167;&#8201;314.111(a)(5)(ii) of this chapter may not be used unless the requirement for adequate and well-controlled studies is                                |
| when             | represented for use in a drug and that, when used in the manufacturing, processing, or packaging of                                                              |
| when             | in emergencies or during hours of the day when necessary drugs cannot be obtained; and transfers of                                                              |
| when             | (u) Ongoing relationship means an association that exists  when a manufacturer and a distributor enter into a                                                    |
| subject to       | including finished dosage forms and bulk drug substances subject to  section 503(b) of the act.                                                                  |
| when             | blood components intended for transfusion; (9) Drug returns, when conducted by a hospital, health care entity, or                                                |
| if               | to reimport a prescription drug or insulin-containing drug if it determines that such reimportation is required for                                              |
| where            | of the FDA District Office in the district where reimportation is sought (addresses found in part 5,                                                             |
| provided that    | stem/progenitor cells or performing diagnostic testing of specimens provided that these specimens are tested together with specimens undergoing                  |
| when             | set forth in paragraph (c) of this section, when the drug sample is delivered; and (4) The                                                                       |
| where            | The practitioner's State license or authorization number or, where a scheduled drug product is requested, the practitioner's                                     |
| if               | the manufacturer and the authorized distributor of record, if the drug sample is requested from an authorized                                                    |
| if               | sample delivered; and the date of the delivery. if                                                                                                               |
| if               | sample delivered; and the date of the delivery. if                                                                                                               |
| when             | set forth in paragraph (c) of this section, when the drug sample is delivered; (4) The receipt                                                                   |
| where            | The practitioner's State license or authorization number, or, where a scheduled drug product is requested, the practitioner's                                    |
| if               | the manufacturer and the authorized distributor of record, if the drug sample is requested from an authorized                                                    |
| if               | sample delivered; and the date of the delivery. if                                                                                                               |
| if               | sample delivered; and the date of the delivery. if                                                                                                               |
| where            | who distribute drug samples and of the sites where  drug samples are stored.                                                                                     |
| provided that    | electronic data transfer) or by any other system, provided that the method for transmission meets the security requirements                                      |
| when             | of nonresponse, and the manufacturer's or distributor's response when such patterns are found; (2) Conducting the annual                                         |
| if               | outside container or packaging of the sample unit, if  any, an ident                                                                                             |
| provided that    | another charitable institution for dispensing to its patients, provided that  the following requirements are met:                                                |
| until            | patient or be distributed to another charitable institution until it has been examined by a licensed practitioner                                                |
| subject to       | (b) The drug origin statement is  subject to the record retention requirements of &#167;&#8201;203.60 and must                                                   |
| when             | (c) Identifying statement not required  when  additional manufacturing processes are completed.                                                                  |
| provided that    | or by photographic imaging (i.e., photocopies or microfiche), provided that the security and authentication requirements described in paragraph                  |
| subject to       | prescription, including finished dosage forms and active ingredients subject to section 503(b) of the Federal Food, Drug, and                                    |
| when             | (9) Drug returns,  when conducted by a hospital, health care entity, or                                                                                          |
| if               | proprietor and the name of the business entity. if                                                                                                               |
| if               | proprietor and the name of the business entity. if                                                                                                               |
| if               | proprietor and the name of the business entity. if                                                                                                               |
| if               | proprietor and the name of the business entity. if                                                                                                               |
| when             | divisions, subsidiaries, and/or affiliate companies within that State when operations are conducted at more than one location                                    |
| if               | minimum, the following factors in reviewing the qual if ications of persons who engage in wholesale distribution                                                 |
| if               | right to deny a license to an applicant if it determines that the granting of such a                                                                             |
| where            | shall provide for suspension or revocation of licenses, where  appropriate, for violations of its provisions.                                                    |
| where            | (iii) Entry into areas  where prescription drugs are held shall be limited to                                                                                    |
| if               | and under appropriate conditions in accordance with requirements, if any, in the labeling of such drugs, or                                                      |
| if               | strength, quality, and purity are not adversely affected. if                                                                                                     |
| until            | quarantined and physically separated from other prescription drugs until  they are destroyed or returned to their supplier.                                      |
| until            | quarantined and physically separated from other prescription drugs until they are either destroyed or returned to the                                            |
| if               | standards of safety, identity, strength, quality, and purity. if                                                                                                 |
| unless           | shall be destroyed, or returned to the supplier, unless examination, testing, or other investigation proves that the                                             |
| if               | The procedure may permit deviation from this requirement,  if  such deviation is temporary and appropriate.                                                      |
| subject to       | Wholesale drug distributors shall be  subject to the provisions of any applicable Federal, State, or                                                             |
| unless           | products, biological drug products, and homeopathic drug products, unless  otherwise exempted under &#167;&#8201;206.7.                                          |
|                  |                   Definitions.                                                                                                                                   |
| if               | are exempt from the requirements of this part if they are designed to copy the active drug                                                                       |
| subject to       | or unique physical characteristics: (1) For a drug subject to premarket approval, FDA may provide an exemption from                                              |
| not subject to   | (2) Any product  not subject to premarket approval is exempt from the requirement of                                                                             |
| if               | approval is exempt from the requirement of &#167;&#8201;206.10 if , based on the product's size, shape, texture,                                                 |
| unless           | introduced or delivered for introduction into interstate commerce unless it is clearly marked or imprinted with a                                                |
| unless           | introduced or delivered for introduction into interstate commerce unless it is clearly marked or imprinted with a                                                |
| subject to       | the review is complete, the drug product is subject to  the requirements of the rule.                                                                            |
| if not           | apply to the terms used in this part, if not  otherwise defined in this section.                                                                                 |
| subject to       | means: (1) For human prescription drugs that are subject to section 505 of the Federal Food, Drug, and                                                           |
| not subject to   | (2) For human prescription drugs that are  not subject to section 505 of the Federal Food, Drug, and                                                             |
| subject to       | (including, but not limited to, drugs that are subject to section 512 of the Federal Food, Drug, and                                                             |
| when             | purposes of registration and listing under this part, when used to modify the term &#8220;registrant,&#8221; &#8220;manufacturer,&#8221; &#8220;repacker,&#8221; |
| when             | or offered for import into the United States. when                                                                                                               |
| when             | or offered for import into the United States. when                                                                                                               |
| subject to       | Repackers, relabelers, and salvagers are  subject to the provisions of this part that are applicable                                                             |
| not subject to   | applicable to repackers, relabelers, and salvagers, but are not subject to the provisions of this part that are applicable                                       |
| where            | is manufacturing, repacking, relabeling, and salvaging drugs and where  those operations are performed.                                                          |
| subject to       | These establishments are  subject to the requirements of this part unless they are                                                                               |
| unless           | are subject to the requirements of this part unless they are required to register and list such                                                                  |
| unless           | or process human whole blood and blood products unless the establishment also manufactures, repacks, or relabels other                                           |
| unless           | exempt from registration and listing under this part unless FDA determines that drug establishment registration and listing                                      |
| where            | feeds, as defined in &#167;&#8201;558.5 of this chapter, where the specifications and/or formulas are not published and                                          |
| provided that    | 832 (21 U.S.C. 151 et seq.)),  provided that this exemption from registration applies only to the                                                                |
| unless           | establishment registration and listing requirements of this part unless  exempt under this section or                                                            |
| if               | this section do not apply to such persons if  they:                                                                                                              |
| subject to       | &#167;&#8201;600.3(u) of this chapter) a human biological product subject to licensing under section 351 of the Public Health                                    |
| unless           | or offered for import into the United States. unless                                                                                                             |
| if               | information submitted by a private label distributor only if it is acting as an authorized agent for                                                             |
| if               | of the owner or operator of each establishment; if  a partnership, the name of each partner;                                                                     |
| if               | of the owner or operator of each establishment; if  a partnership, the name of each partner;                                                                     |
| if               | of the owner or operator of each establishment; if  a partnership, the name of each partner;                                                                     |
| subject to       | and (h) Additionally, with respect to foreign establishments subject to registration, the name, mailing address, telephone number, and                           |
| if               | December 31 of the year of initial registration, if  the initial registration occurs prior to October 1.                                                         |
| if               | occurred since the last registration, registrants must cert if y that no changes have occurred.                                                                  |
| subject to       | Each finished drug product or unfinished drug  subject to the listing requirements of this part must have                                                        |
| if               | of 10 or 11 digits (5-3-2 or 6-3-2). if                                                                                                                          |
| if               | a total NDC length of 10 digits (4-4-2). if                                                                                                                      |
| if               | Director may be used for the following HCT/Ps if they are minimally manipulated: Hematopoietic stem/progenitor cells derived                                     |
| subject to       | relabeling, or private label distribution of a drug subject to listing under this part must apply for an                                                         |
| when             | is an NDC proposed for assignment by FDA, when is an NDC assigned by FDA, and how                                                                                |
| when             | An NDC is proposed for assignment by FDA when it is submitted for the first time with                                                                            |
| if               | (ii) In addition,  if a drug is distributed under the trade name                                                                                                 |
| if               | section and is not reserved for a d if ferent drug or was not previously assigned to                                                                             |
| when             | FDA will assign the NDC to a drug when it receives listing information required for that drug                                                                    |
| if               | of 2 years from the date of submission. if                                                                                                                       |
| unless           | (d) of this section must be submitted electronically unless  FDA grants a waiver under &#167;&#8201;207.65.                                                      |
| when             | a new and unique NDC for a drug when there is a change, after the drug is                                                                                        |
| when             | new NDC must include a new product code when there is a change to any of the                                                                                     |
| if               | (1) The drug's established name or proprietary name, if  any;                                                                                                    |
| when             | existing product code in NDCs assigned by FDA. when                                                                                                              |
| if               | size or type, including the immediate unit-of-use container, if any, the proposed new NDC must include only                                                      |
| unless           | package code and retain the existing product code unless all available package codes have already been combined                                                  |
| if               | A product may be deemed to be misbranded if an NDC is used: (1) To represent a                                                                                   |
| not subject to   | a drug; or (3) On products that are not subject to parts 207, 607 of this chapter, or 1271                                                                       |
| if               | as described in &#167;&#8201;207.33, before marketing was discontinued. if                                                                                       |
| when             | paragraph include the registrant's labeler code, except that when the drug is manufactured for commercial distribution under                                     |
| if               | The listed drug's established name and proprietary name, if any; (4) The name and quantity of each                                                               |
| if               | The listed drug's established name and proprietary name, if any; (4) The name and quantity of each                                                               |
| if               | the Drug Master File or Veterinary Master File, if any, that describes the manufacture of the drug;                                                              |
| subject to       | the drug; (10) For each drug that is subject to the imprinting requirements of part 206 of this                                                                  |
| where            | name and Unique Facility Identifier of the establishment where the registrant who lists the drug manufactures it                                                 |
| where            | name and Unique Facility Identifier of the establishment where the registrant who lists the drug manufactures it                                                 |
| if               | under section 202 of the Controlled Substances Act, if applicable; (14) Advertisements: (i) A representative sampling of                                         |
| not subject to   | advertisements for a human prescription drug that is not subject to section 505 of the Federal Food, Drug, and                                                   |
| if               | those advertisements described in &#167;&#8201;202.1(l)(1) of this chapter. if                                                                                   |
| not subject to   | advertisements for a human prescription drug that is not subject to section 505 of the Federal Food, Drug, and                                                   |
| where            | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| subject to       | (A) For each human nonprescription drug  subject to section 505 of the Federal Food, Drug, and                                                                   |
| where            | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| not subject to   | (B) For each human nonprescription drug  not subject to section 505 of the Federal Food, Drug, and                                                               |
| where            | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| subject to       | (A) For each animal drug that is  subject to section 512 of the Federal Food, Drug, and                                                                          |
| where            | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| where            | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| where            | that only one representative label need be submitted where differences exist only in the quantity of contents                                                    |
| if               | commercial distribution: (1) The drug's over-the-counter monograph reference, if any; and (2) The date on which the                                              |
| where            | name and Unique Facility Identifier of every establishment where repacking or relabeling is performed for the drug                                               |
| where            | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| subject to       | (i) For each human nonprescription drug  subject to section 505 of the Federal Food, Drug, and                                                                   |
| where            | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| not subject to   | (ii) For each human nonprescription drug  not subject to section 505 of the Federal Food, Drug, and                                                              |
| where            | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| subject to       | (i) For each animal drug that is  subject to section 512 of the Federal Food, Drug, and                                                                          |
| where            | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| where            | representative container or carton label need be submitted where differences exist only in the quantity of contents                                              |
| where            | that only one representative label need be submitted where differences exist only in the quantity of contents                                                    |
| not subject to   | advertisements for a human prescription drug that is not subject to section 505 of the Federal Food, Drug, and                                                   |
| if               | including advertisements described in &#167;&#8201;202.1(l)(1) of this chapter. if                                                                               |
| where            | name and Unique Facility Identifier for each establishment where  the registrant salvages the drug.                                                              |
| not subject to   | basis for its belief that the drug is not subject to section 505 or 512 of the Federal Food,                                                                     |
| when             | What information must registrants submit  when  updating listing information and                                                                                 |
| subject to       | For each listed drug, certify that no changes subject to reporting under paragraph (b)(1)(iv) of this section have                                               |
| if               | part; or (2) For each listed drug, cert if y that no changes subject to reporting under                                                                          |
| subject to       | encouraged to submit listing information for every drug subject to listing under this part prior to commercial distribution                                      |
| unless           | transmitted to FDA electronically in accordance with &#167;&#8201;207.61(a) unless FDA has granted a request for waiver of                                       |
| if               | FDA will grant a waiver request  if FDA determines that the use of electronic means                                                                              |
| where            | and a U.S. telephone number and mailing address where  FDA can contact the registrant.                                                                           |
| if               | FDA may limit its duration and will spec if y terms of the waiver and provide information                                                                        |
| subject to       | Registrants  subject to the registration requirements of this part must designate                                                                                |
| subject to       | Registrants of foreign establishments  subject to this part must designate a single United States                                                                |
| where            | mailbox, answering machine or service, or other place where a person acting as the United States agent                                                           |
| if               | information and/or documents to the United States agent. if                                                                                                      |
| unless           | (12), &#167;&#8201;207.53(b) and (c), or &#167;&#8201;207.54(a) or (c). unless                                                                                   |
| not subject to   | has been determined that a particular drug is not subject to section 505 or 512 of the Federal Food,                                                             |
| when             | required under this part is to provide information when the FDA determines in writing that it is                                                                 |
| if               | (c) Patient labeling will be required  if the FDA determines that one or more of                                                                                 |
| if               | Each heading shall contain the spec if ic information as follows: (1) The brand name                                                                             |
| unless           | The Medication Guide may not identify an indication  unless the indication is identified in the indications and                                                  |
| if               | Guide shall contain directions regarding what to do if any of the contraindications apply to a patient,                                                          |
| if               | the importance of adhering to the dosing instructions, if this is particularly important; (ii) A statement describing                                            |
| if               | the importance of adhering to the dosing instructions, if this is particularly important; (ii) A statement describing                                            |
| if               | the importance of adhering to the dosing instructions, if this is particularly important; (ii) A statement describing                                            |
| where            | taking a scheduled dose(s) of the drug product, where  there are data to support the advice, and                                                                 |
| where            | taking a scheduled dose(s) of the drug product, where  there are data to support the advice, and                                                                 |
| when             | as tobacco or alcohol) that patients should avoid when using the medication; (ii) A statement of the                                                             |
| if               | followed by a statement or statements of spec if ic, important precautions patients should take to ensure                                                        |
| if               | followed by a statement or statements of spec if ic, important precautions patients should take to ensure                                                        |
| if               | followed by a statement or statements of spec if ic, important precautions patients should take to ensure                                                        |
| if               | followed by a statement or statements of spec if ic, important precautions patients should take to ensure                                                        |
| if               | (vi) A statement of special precautions,  if any, that apply to the safe and effective                                                                           |
| if               | (ii) A statement of the risk,  if there is one, of patients' developing dependence on                                                                            |
| if               | subheadings may be interspersed throughout the Medication Guide, if  appropriate.                                                                                |
| where            | (d) The label of each container or package,  where the container label is too small, of drug                                                                     |
| when             | Medication Guide is required under this part shall, when the product is dispensed to a patient (or                                                               |
| unless           | to each patient (or to the patient's agent) unless  an exemption applies under &#167;&#8201;208.26.                                                              |
| not subject to   | (f) An authorized dispenser or wholesaler is  not subject to section 510 of the Federal Food, Drug, and                                                          |
| if               | to receive a Medication Guide because of sign if icant concerns about the effect of a Medication                                                                 |
| subject to       | the licensed practitioner who prescribes a drug product subject to this part determines that it is not in                                                        |
| subject to       | the authorized dispenser of a prescription drug product subject to this part shall provide a Medication Guide to                                                 |
| when             | Medication Guide to any patient who requests information when the drug product is dispensed regardless of any                                                    |
| subject to       | responsible for the failure to comply, shall be subject to  regulatory action.                                                                                   |
| subject to       | &#167;&#8201;1271.3(d) of this chapter, that are drugs ( subject to review under an application submitted under section 505                                      |
| subject to       | is responsible for the failure to comply, is subject to  regulatory action.                                                                                      |
| unless           | be considered to supplement, not supersede, each other, unless  the regulations explicitly provide otherwise.                                                    |
| if               | operations in which he or she is engaged. if                                                                                                                     |
| subject to       | If a person engages in only some operations subject to the regulations in this part, in parts 211,                                                               |
| subject to       | as described in &#167;&#8201;312.21(a) of this chapter, is subject to the statutory requirements set forth in 21 U.S.C.                                          |
| when             | the act shall be applicable to such terms when used in this part and in parts 211,                                                                               |
| subject to       | The manufacture of medicated feeds is  subject to  the requirements of part 225 of this chapter.                                                                 |
| subject to       | The manufacture of medicated premixes is  subject to  the requirements of part 226 of this chapter.                                                              |
| unless           | do not supersede the regulations in this part unless  the regulations explicitly provide otherwise.                                                              |
| if               | shall not be enforced for OTC drug products if the products and all their ingredients are ordinarily                                                             |
| until            | Therefore,  until further notice, regulations under parts 110 and 117                                                                                            |
| where            | parts 110 and 117 of this chapter, and where applicable, parts 113 through 129 of this chapter,                                                                  |
| if               | to assure that no errors have occurred or, if errors have occurred, that they have been fully                                                                    |
| until            | product containers, closures, in-process materials, and drug products until the condition is corrected or determined by competent                                |
| when             | micro-organisms, dust, humidity, and temperature shall be provided when appropriate for the manufacture, processing, packing, or holding                         |
| when             | and particulate matter air filters, shall be used when  appropriate on air supplies to production areas.                                                         |
| where            | In areas  where air contamination occurs during production, there shall be                                                                                       |
| where            | (b) Drains shall be of adequate size and,  where connected directly to a sewer, shall be provided                                                                |
| unless           | Rodenticides, insecticides, and fungicides shall not be used  unless registered and used in accordance with the Federal                                          |
| where            | maintaining equipment; (2) Maintenance and cleaning schedules, including, where appropriate, sanitizing schedules; (3) A description in sufficient               |
| where            | computer or related system shall be maintained except where certain data, such as calculations performed in connection                                           |
| if               | by one person and checking by another person if such equipment is used in conformity with this                                                                   |
| when             | Fiber-releasing filters may be used  when it is not possible to manufacture such products                                                                        |
| if               | pore size rating of 0.2 micron (0.45 micron if the manufacturing conditions so dictate) shall subsequently be                                                    |
| until            | containers, and closures shall be stored under quarantine until they have been tested or examined, whichever is                                                  |
| until            | containers, and closures shall be withheld from use until the lot has been sampled, tested, or examined,                                                         |
| where            | and the quantity needed for analysis and reserve where  required by &#167;&#8201;211.170.                                                                        |
| when             | The containers of components selected shall be cleaned when necessary in a manner to prevent introduction of                                                     |
| when             | equipment and aseptic sampling techniques shall be used when  necessary.                                                                                         |
| if               | sample subdivisions shall not be composited for testing. if                                                                                                      |
| if               | Spec if ic identity tests,                                                                                                                                       |
| provided that    | be accepted from the supplier of a component, provided that at least one specific identity test is conducted                                                     |
| provided that    | be accepted from the supplier of a component, provided that at least one specific identity test is conducted                                                     |
| provided that    | of testing may be accepted from the supplier, provided that at least a visual identification is conducted on                                                     |
| provided that    | of testing may be accepted from the supplier, provided that at least a visual identification is conducted on                                                     |
| when             | (4) When appropriate, components shall be microscopically examined. when                                                                                         |
| if               | Deviation from this requirement is permitted  if  such deviation is temporary and appropriate.                                                                   |
| where            | product containers and closures shall be clean and, where indicated by the nature of the drug, sterilized                                                        |
| where            | (d) Standards or specifications, methods of testing, and,  where indicated, methods of cleaning, sterilizing, and processing to                                  |
| when             | containers must be reasonably resistant to fading, durable when exposed to atmospheric conditions, and not readily soluble                                       |
| if               | to the batch by one person and ver if ied by a second person or,                                                                                                 |
| if               | be performed by one person and independently ver if ied by a second person, or,                                                                                  |
| when             | at all times to indicate their contents and, when  necessary, the phase of processing of the batch.                                                              |
| where            | In cases  where only one of a particular type of equipment                                                                                                       |
| where            | include, but are not limited to, the following, where appropriate: (1) Tablet or capsule weight variation; (2)                                                   |
| where            | previous acceptable process average and process variability estimates where possible and determined by the application of suitable                               |
| where            | previous acceptable process average and process variability estimates where possible and determined by the application of suitable                               |
| if               | Deviation from established time limits may be acceptable  if such deviation does not compromise the quality of                                                   |
| unless           | contents of the same drug product, is prohibited unless the labeling from gang-printed sheets is adequately differentiated                                       |
| if               | of labeling and packaging lines to each d if ferent strength of each d                                                                                           |
| when             | product finished and the quantity of labeling issued when such discrepancies are outside narrow preset limits based                                              |
| if               | reconciliation is waived for cut or roll labeling if a 100-percent examination for correct labeling is performed                                                 |
| if               | an OTC drug product (except a dermatological, dent if rice, insulin, or lozenge product) for retail sale                                                         |
| if               | or more indicators or barriers to entry which, if breached or missing, can reasonably be expected to                                                             |
| if               | to increase the likelihood that consumers will discover if a product has been tampered with, the package                                                         |
| when             | shall be designed to and shall remain intact when handled in a reasonable manner during manufacture, distribution,                                               |
| if               | In order to alert consumers to the spec if ic tamper-evident feature(s) used, each retail package of                                                             |
| if               | paragraph (b) of this section uses an ident if ying characteristic, that characteristic is required to be                                                        |
| if               | of this chapter and should be clearly ident if ied on the envelope as a &#8220;Request for                                                                       |
| subject to       | (e) OTC drug products  subject to  approved new drug applications.                                                                                               |
| if               | for both the reconstituted and unreconstituted drug products. if                                                                                                 |
| provided that    | are exempt from the requirements of this section, provided that they meet appropriate standards or specifications as demonstrated                                |
| if               | not be enforced for human OTC drug products if their labeling does not bear dosage limitations and                                                               |
| if               | Deviation from this requirement is permitted  if  such deviation is temporary and appropriate.                                                                   |
| if               | can be readily determined to facilitate its recall if  necessary.                                                                                                |
| subject to       | component, drug product container, or closure that is subject to  deterioration.                                                                                 |
| as soon as       | and/or pyrogen testing, provided such testing is completed as soon as  possible.                                                                                 |
| until            | conducted, including drug product testing at appropriate intervals, until the tentative expiration date is verified or the                                       |
| if               | of the drug product containing the active ingredient if the expiration dating period of the drug product                                                         |
| if               | of the drug product containing the active ingredient if the expiration dating period of the drug product                                                         |
| unless           | least once a year for evidence of deterioration unless visual examination would affect the integrity of the                                                      |
| if               | after the expiration date of the drug product if the expiration dating period of the drug product                                                                |
| if               | after the expiration date of the drug product if the expiration dating period of the drug product                                                                |
| if               | Such drug product shall not be marketed  if detectable levels are found when tested according to                                                                 |
| when             | not be marketed if detectable levels are found when tested according to procedures specified in &#8216;Procedures for                                            |
| where            | inspection during the retention period at the establishment where  the activities described in such records occurred.                                            |
| subject to       | These records or copies thereof shall be  subject to photocopying or other means of reproduction as part                                                         |
| where            | number of batches, whether approved or rejected, and, where  applicable, records associated with the batch.                                                      |
| if               | assure that the responsible officials of the firm, if they are not personally involved in or immediately                                                         |
| provided that    | product, then individual equipment logs are not required, provided that lots or batches of such product follow in                                                |
| where            | In cases  where dedicated equipment is employed, the records of cleaning,                                                                                        |
| if               | performing and double-checking the cleaning and maintenance (or, if the cleaning and maintenance is performed using automated                                    |
| if               | name of the supplier; the supplier's lot number(s) if  known; the receiving code as spec                                                                         |
| if               | The name and location of the prime manufacturer,  if  d                                                                                                          |
| if               | The name and location of the prime manufacturer,  if  d                                                                                                          |
| if               | dated, and signed; (b) Documentation that each sign if icant step in the manufacture, processing, packing, or                                                    |
| where            | with identification of source (that is, location from where sample was obtained), quantity, lot number or other                                                  |
| where            | or measure of sample used for each test, where  appropriate.                                                                                                     |
| where            | product complaints shall be maintained at the establishment where the drug product involved was manufactured, processed, or                                      |
| if               | such file may be maintained at another facility if the written records in such files are readily                                                                 |
| until            | records involving a drug product shall be maintained until at least 1 year after the expiration date                                                             |
| where            | The written record shall include the following information, where known: the name and strength of the drug                                                       |
| where            | include the findings of the investigation and followup. where                                                                                                    |
| where            | the investigation shall be maintained at the establishment where  the investigation occurred in accordance with &#167;&#8201;211.180(c).                         |
| where            | of the responsible person making such a determination. where                                                                                                     |
| if               | or shipped before or during their return, or if the condition of the drug product, its container,                                                                |
| unless           | product, the returned drug product shall be destroyed unless examination, testing, or other investigations prove the drug                                        |
| if               | such conditions, salvaging operations may be conducted only if there is (a) evidence from laboratory tests and                                                   |
| where            | laboratory tests and assays (including animal feeding studies where applicable) that the drug products meet all applicable                                       |
| subject to       | and disposition shall be maintained for drug products subject to  this section.                                                                                  |
| when             | Other definitions of these words may apply  when they are used in other parts of this                                                                            |
| when             | or other material used in PET drug production, when tested according to the described analytical procedures, meets                                               |
| when             | determine the need for an investigation, conduct investigations when  necessary, and take appropriate corrective actions.                                        |
| when             | drug, or give erroneous or invalid test results when improperly used or maintained, is clean, suitable for                                                       |
| if               | any lot that does not meet its spec if ications, including any expiration date                                                                                   |
| if               | that PET drug product complies with written spec if ications by examining a cert                                                                                 |
| if               | inactive ingredient used in that PET drug product. if                                                                                                            |
| if               | determine that each lot complies with written spec if ications by examining a cert                                                                               |
| if               | However,  if you use as an inactive ingredient a product                                                                                                         |
| if               | components designated by names and codes sufficiently spec if ic to indicate any special quality characteristic; (4)                                             |
| if               | are permitted in the amount of component necessary if  they are spec                                                                                             |
| until            | materials to ensure that the materials are controlled until required tests or other verification activities have been                                            |
| when             | are not fully verified through finished-product testing or when only the initial sub-batch in a series is                                                        |
| when             | are not fully verified through finished-product testing or when only the initial sub-batch in a series is                                                        |
| where            | What requirements apply to the laboratories  where I test components, in-process materials, and finished PET                                                     |
| if               | You must establish spec if ications for each PET drug product, including criteria                                                                                |
| until            | PET drug product is not given final release until the following are done: (1) An appropriate laboratory                                                          |
| if               | to test results that would have been obtained if the test had been started within the 30-hour                                                                    |
| if               | approve the conditional final release of the product if you meet the following conditions: (i) You have                                                          |
| if               | approve the conditional final release of the product if you meet the following conditions: (i) You have                                                          |
| if               | approve the conditional final release of the product if you meet the following conditions: (i) You have                                                          |
| when             | malfunction; (v) If you obtain an out-of-specification result when testing the reserve sample, you immediately notify the                                        |
| if               | (2) Even  if the criteria in paragraph (f)(1) of this section                                                                                                    |
| if               | (2) Even  if the criteria in paragraph (f)(1) of this section                                                                                                    |
| until            | release another batch of the PET drug product until you have corrected the problem concerning the malfunction                                                    |
| if               | What actions must I take  if a batch of PET drug product does not                                                                                                |
| if               | What do I do  if I receive a complaint about a PET drug                                                                                                          |
| if               | medicated feed) shall be deemed to be adulterated if the methods used in, or the facilities or                                                                   |
| subject to       | listings and a medicated feed mill license are subject to  the requirements of &#167;&#8201;510.301 of this chapter.                                             |
| unless           | fertilizers, herbicides, insecticides, fungicides, rodenticides, and other pesticides unless such articles are approved drugs, indexed drugs, or                 |
| when             | in assuring their identity, strength, quality, and purity when  incorporated into products.                                                                      |
| when             | date of receipt, the condition of the drug when  received, and the return of any damaged drugs.                                                                  |
| if               | the same as the previous day's closing inventory if this amount has been established to be correct);                                                             |
| when             | the purpose of paragraph (b)(7) of this section. when                                                                                                            |
| until            | are affected by this discrepancy shall be detained until  the discrepancy is reconciled.                                                                         |
| unless           | methods, at periodic intervals during the calendar year, unless  otherwise specified in this chapter.                                                            |
| subject to       | drugs, only one of the drugs need be subject to analysis each time, provided the one tested is                                                                   |
| where            | record of such action maintained on the premises. where                                                                                                          |
| where            | Corrective action shall include provisions for discontinuing distribution where the medicated feed fails to meet the labeled                                     |
| until            | production of the particular feed shall not begin until it has been determined that proper control procedures                                                    |
| subject to       | in process, or finished medicated feed shall be subject to all reasonable and effective procedures to prevent unsafe                                             |
| where            | other equally effective procedures: (1) Such procedures shall, where appropriate, consist of physical means (vacuuming, sweeping, or                             |
| if               | utilized, the flush material shall be properly ident if ied, stored, and used in a manner to                                                                     |
| if               | prevent unsafe contamination of feeds with residual drugs. if                                                                                                    |
| if               | (a) Appropriate labeling ident if ies the medicated feed, and provides the user                                                                                  |
| where            | (3) In those instances  where medicated feeds are distributed in bulk, complete labeling                                                                         |
| when             | continuous production run, any additional manufacturing directions including, when  indicated, the settings of equipment.                                        |
| where            | In those instances  where the finished feed is stored in bulk and                                                                                                |
| unless           | fertilizers, herbicides, insecticides, fungicides, rodenticides, and other pesticides unless such articles are approved or index listed for                      |
| if not           | maintained identifying the formulation, date of mixing, and if not  for own use, date of shipment.                                                               |
| when             | the production of a Type A medicated article(s) when adequate inspection and checking procedures or other quality                                                |
| subject to       | Type A medicated articles requiring approved NADAs are subject to  the requirements of &#167;&#8201;514.80 of this chapter.                                      |
| subject to       | A medicated articles listed in the index are subject to  the requirements of &#167;&#8201;516.165 of this chapter.                                               |
| when             | (b) Provide adequate lighting and ventilation, and  when necessary for the intended production or control purposes,                                              |
| if               | safeguards to avoid any buildup above the spec if ied levels of the drug components in any                                                                       |
| until            | such Type A medicated article(s) shall not begin until it has been determined that proper control procedures                                                     |
| until            | within limitations, each batch should again be assayed until  five consecutive batches are within limitations.                                                   |
| provided that    | the preparation of the Type A medicated article(s), provided that the variations are stated in the master formula;                                               |
| when             | continuous production run, any additional manufacturing directions including, when indicated, the settings of equipment that have been                           |
| if               | or destruction of the Type A medicated article(s), if  necessary.                                                                                                |
| where            | be evaluated by competent and responsible personnel and, where  indicated, appropriate action shall be taken.                                                    |
| where            | rationale except possibly in those relatively uncommon instances where the condition is directly related to hypothyroidism and                                   |
| when             | system stimulants with or without other drug substances when offered for or as adjuncts to the treatment,                                                        |
| when             | Such combinations  when offered for obesity in humans directly attributable to                                                                                   |
| subject to       | Drug Administration showing that such products have been subject to abuse and misuse on a fairly large scale,                                                    |
| if               | of other ingredients, will be regarded as misbranded if they are labeled with directions for use in                                                              |
| unless           | amyl nitrite inhalant will be regarded as misbranded unless the labeling on or within the package from                                                           |
| if               | or dispensed contrary to this statement of policy if  such act occurs after July 1, 1969.                                                                        |
| subject to       | the Food and Drug Administration as misbranded and subject to regulatory proceedings, unless such recommendations are covered by                                 |
| unless           | Administration as misbranded and subject to regulatory proceedings, unless such recommendations are covered by the approval of                                   |
| if               | of the Federal Food, Drug, and Cosmetic Act if its label fails to bear in a prominent                                                                            |
| subject to       | permanganate tablets intended for human use are drugs subject to section 503(b)(1) of the Federal Food, Drug, and                                                |
| if               | Such drugs will be regarded as misbranded  if at any time prior to dispensing the label                                                                          |
| unless           | of this chapter will be regarded as misbranded unless  the label bears the statement, &#8220;Rx only.&#8221;                                                     |
| when             | (3) These drugs will be regarded as misbranded  when intended for veterinary use unless the label bears                                                          |
| unless           | regarded as misbranded when intended for veterinary use unless the label bears the legend, &#8220;Caution: Federal law                                           |
| if               | a drug labeled and marketed for veterinary use if such drug contains not more than 50 percent                                                                    |
| unless           | and (2) and section 502(j) of the act unless , among other things, all of the following                                                                          |
| unless           | of the Federal Food, Drug, and Cosmetic Act unless  it is labeled with the statement &#8220;Rx only.&#8221;                                                      |
| unless           | sections 502 (f)(2) and (j) of the act unless its labeling bears a statement to the effect                                                                       |
| unless and until | This statement of policy will remain in effect  unless and until replaced by a monograph resulting from the OTC                                                  |
| subject to       | containing drugs will be regarded as misbranded and subject to regulatory proceedings unless the label bears the statement                                       |
| unless           | regarded as misbranded and subject to regulatory proceedings unless the label bears the statement &#8220;Rx only,&#8221; and                                     |
| until            | new drug application (or required supplement thereto) either until a notice of opportunity for hearing is issued                                                 |
| until            | new drug application (or required supplement thereto) either until a notice of opportunity for hearing is issued                                                 |
| if               | or until January 31, 1978, whichever comes first, if all the following conditions were met after September                                                       |
| where            | a supplement to provide for a revised formulation where  appropriate to comply with this order.                                                                  |
| unless           | obtained from use of the drug as recommended, unless such information is a part of the new                                                                       |
| where            | use of hexachlorophene shall be limited to situations where an alternative preservative has not yet been shown                                                   |
| where            | use of hexachlorophene shall be limited to situations where an alternative preservative has not yet been shown                                                   |
| where            | use of hexachlorophene shall be limited to situations where an alternative preservative has not yet been shown                                                   |
| where            | use of hexachlorophene shall be limited to situations where an alternative preservative has not yet been shown                                                   |
| unless           | and will in any event be deemed misbranded unless it contains a conspicuous front panel statement that                                                           |
| where            | hexachlorophene content on the labeling of the products, where  required, shall be on a w/w basis.                                                               |
| unless           | of the Federal Food, Drug, and Cosmetic Act unless  specifically exempted in &#167;&#8201;290.2.                                                                 |
| when             | IV of the Federal Controlled Substances Act shall, when dispensed to or for a patient, contain the                                                               |
| when             | following warning on the label of certain drugs when dispensed to or for a patient: &#8220;Caution: Federal                                                      |
| when             | the act shall be applicable to such terms when  used in this part 299.                                                                                           |
| if               | to designate an official name for any drug if he determines that such action is necessary or                                                                     |
| if               | of a drug must bear its established name, if there is one, to the exclusion of any                                                                               |
| if               | of a drug must bear its established name, if there is one, to the exclusion of any                                                                               |
| if               | pursuant to section 508 of the act; (2) if no such official name has been designated for                                                                         |
| if               | pursuant to section 508 of the act; (2) if no such official name has been designated for                                                                         |
| if               | of a new drug substance may be delayed if a simple and useful nonproprietary name does not                                                                       |
| if               | of a new drug substance may be delayed if a simple and useful nonproprietary name does not                                                                       |
| if               | either the compendial name of the drug or, if there is no compendial name, the common and                                                                        |
| when             | the provisions of section 508 of the act when the agency determines that: (1) The USAN or                                                                        |
| unless           | from any name recognized in an official compendium unless such drug complies in identity with the identity                                                       |
| when             | or ingredient has some unique effectiveness or composition, when , in fact, the drug or ingredient is                                                            |
| when             | or ingredient has some unique effectiveness or composition, when , in fact, the drug or ingredient is                                                            |
| if               | drug or any ingredient thereof, the established name, if such there be, corresponding to such proprietary name                                                   |
| if               | drug or any ingredient thereof, the established name, if such there be, corresponding to such proprietary name                                                   |
| if               | used in the running text: Provided, however, That if the proprietary name or designation is used in                                                              |
| if               | such column of running text: Provided, however, That if the proprietary name or designation is used in                                                           |
| if               | prescription drug containing two or more active ingredients, if the advertisement bears a proprietary name or designation                                        |
| if               | more than one preparation (the individual preparations d if fering from each other as to quantities of                                                           |
| when             | side effects, contraindications, and effectiveness: (1) When required. when                                                                                      |
| unless           | audio and visual parts of the presentation and unless adequate provision is made for dissemination of the                                                        |
| if               | only the proprietary name of the drug product, if  any; the established name of the drug product,                                                                |
| if               | only the proprietary name of the drug product, if  any; the established name of the drug product,                                                                |
| subject to       | price information including, but not limited to, those subject to the requirements of &#167;&#8201;200.200 of this chapter, are                                  |
| if               | are exempt from the requirements of this section if they meet all of the conditions contained in                                                                 |
| subject to       | Reminder advertisements, other than those  subject to the requirements of &#167;&#8201;200.200 of this chapter, are                                              |
| if               | the manufacturer, packer, or distributor will be not if ied either in the publication of the conclusions                                                         |
| subject to       | Reminder advertisements, other than those  subject to the requirements of &#167;&#8201;200.200 of this chapter, are                                              |
| if               | for use by registered pharmacists in compounding prescriptions if the drug otherwise complies with the conditions for                                            |
| if               | by reason of the omission of appropriate qual if ication or pertinent information, that part or theme                                                            |
| when             | for purposes claimed in the advertisement; for example, when an advertisement contains a broad claim that a                                                      |
| if               | and any effective, approved, or permitted supplement thereto. if                                                                                                 |
| subject to       | such uses would be permitted were the drug subject to  paragraph (e)(4)(iii) of this section.                                                                    |
| if               | recognized as safe and effective among experts qual if ied by scient                                                                                             |
| if               | considered to be in violation of this section if the presentation of true information relating to side                                                           |
| if               | section 502(n) of the act, among other reasons, if  it:                                                                                                          |
| when             | more effective than another drug in some particular when it has not been demonstrated to be safer                                                                |
| unless           | effect (information concerning placebo effect is not required unless the advertisement promotes the drug for use by                                              |
| when             | a way that suggests they have clinical significance when in fact no such clinical significance has been                                                          |
| unless           | provided by the fixed combination drug is indicated, unless such condition is included in the uses permitted                                                     |
| unless           | individuals without disclosing that the subjects were normal, unless the drug is intended for use on normal                                                      |
| if               | effects, derived from pooling data from various insign if icant or dissimilar studies in a way that                                                              |
| when             | from large or significant studies supporting favorable conclusions when  such is not the case.                                                                   |
| if               | drug derived from patients treated with dosages d if ferent from those recommended in approved or permitted                                                      |
| subject to       | or permitted labeling if the drug advertised is subject to section 505 of the act, or, in the                                                                    |
| if               | drug derived from patients treated with dosages d if ferent from those recommended in approved or permitted                                                      |
| if               | that include some patients treated with dosages d if ferent from those authorized,                                                                               |
| when             | of other classes of patients or disease conditions when  such is not the case.                                                                                   |
| if               | otherwise violative of section 502(n) of the act if it: (i) Contains favorable information or conclusions from                                                   |
| when             | the information relating to side effects and contraindications, when such information is contained in a distinct part                                            |
| when             | facing pages are part of the same advertisement when one page contains information relating to side effects                                                      |
| when             | effects and contraindications or the significant dosage considerations, when dosage recommendations are included in an advertisement, especially                 |
| when             | page, information relating to side effects and contraindications when such information is in a distinct part of                                                  |
| when             | a prominent reference to its presence and location when it is presented as a distinct part of                                                                    |
| subject to       | (l)(1) Advertisements  subject to section 502(n) of the act include advertisements in                                                                            |


## Entities

| Entities                                     | Context                                                                                                                                                  |
|:---------------------------------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------|
| Food                                         | Food  and Drugs.                                                                                                                                         |
| Scope                                        | Scope .                                                                                                                                                  |
| Blood                                        | Blood and blood components intended for transfusion are excluded                                                                                         |
| Purpose                                      | Purpose .                                                                                                                                                |
| Food                                         | Food  and Drug Administration.                                                                                                                           |
| United States                                | manufactured in a State and exported from the United States may be reimported by anyone other than its                                                   |
| Research                                     | regulated by the Center for Drug Evaluation and Research may be made to the Office of Compliance,                                                        |
| Research                                     | regulated by the Center for Biologics Evaluation and Research may be made to the Food and Drug                                                           |
| Rm                                           | 71,  Rm .                                                                                                                                                |
| G112                                         | G112 , Silver Spring, MD 20993-0002.                                                                                                                     |
| Blood                                        | Blood establishments relying on the exclusion in this paragraph                                                                                          |
| Sample                                       | Sample  distribution by mail or common carrier.                                                                                                          |
| Sample                                       | Sample distribution by means other than mail or common                                                                                                   |
| Risperidone                                  | (1 mg) returned to manufacturer&#8221; or simply &#8220; Risperidone (1 mg)/50/returned to manufacturer.&#8221; (3) Each drug manufacturer               |
| Drug                                         | Drug  sample storage and handling requirements.                                                                                                          |
| Drug                                         | Drug  sample forms.                                                                                                                                      |
| Fulfillment                                  | Fulfillment houses, shipping and mailing services, comarketing agreements, and                                                                           |
| Investigation                                | Investigation  and notification requirements.                                                                                                            |
| Surveillance, Office                         | to the Division of Compliance Risk Management and Surveillance, Office of Compliance, Center for Drug Evaluation and Research,                           |
| Research                                     | regulated by the Center for Drug Evaluation and Research shall be made to the Division of Compliance                                                     |
| Research                                     | regulated by the Center for Biologics Evaluation and Research shall be made to the Food and Drug                                                         |
| Rm                                           | 71,  Rm .                                                                                                                                                |
| G112                                         | G112 , Silver Spring, MD 20993-0002.                                                                                                                     |
| Sample                                       | Sample  lot or control numbers; labeling of sample units.                                                                                                |
| Drug                                         | Drug sample inventory discrepancies and reconciliation problems shall be                                                                                 |
| Dosage                                       | proprietary and established name of the drug; (2) Dosage ;                                                                                               |
|                                              |                       (3) Container size;                                                                                                                |
|                                              |                       (4) Number of containers;                                                                                                          |
| Request                                      | Request  and receipt forms, reports, and records.                                                                                                        |
| Request                                      | Request and receipt forms, reports, records, and other documents                                                                                         |
| Application                                  | Application  for a reward.                                                                                                                               |
| Research                                     | Office of Compliance, Center for Drug Evaluation and Research , Food and Drug Administration, 10903 New Hampshire                                        |
| Research, Office                             | and Drug Administration, Center for Biologics Evaluation and Research, Office of Compliance and Biologics Quality (ATTN: Director), Document             |
| Rm                                           | 71,  Rm .                                                                                                                                                |
| G112                                         | G112 , Silver Spring, MD 20993-0002, as appropriate.                                                                                                     |
| Scope                                        | Scope .                                                                                                                                                  |
| Purpose                                      | Purpose .                                                                                                                                                |
| Wholesale                                    | Wholesale  drug distributor licensing requirement.                                                                                                       |
| Minimum                                      | Minimum  required information for licensure.                                                                                                             |
| Minimum                                      | Minimum  qualifications.                                                                                                                                 |
| Federal                                      | (1) Any convictions of the applicant under any Federal , State, or local laws relating to drug                                                           |
| Federal                                      | revocation of licenses upon conviction of violations of Federal , State, or local drug laws or regulations,                                              |
| Minimum                                      | Minimum requirements for the storage and handling of prescription                                                                                        |
| United States PharmacopeiaNational Formulary | such as the United States Pharmacopeia/National Formulary (USP/NF). United States PharmacopeiaNational Formulary                                         |
| Wholesale                                    | Wholesale drug distributors shall establish, maintain, and adhere to                                                                                     |
| Wholesale                                    | Wholesale drug distributors shall include in their written policies                                                                                      |
| Wholesale                                    | Wholesale drug distributors shall establish and maintain lists of                                                                                        |
| Wholesale                                    | Wholesale drug distributors shall operate in compliance with applicable                                                                                  |
| Wholesale                                    | Wholesale drug distributors shall be subject to the provisions                                                                                           |
| Scope                                        | Scope .                                                                                                                                                  |
| Drug                                         | Drug product means a finished dosage form, e.g., a                                                                                                       |
| Solid                                        | Solid oral dosage form means capsules, tablets, or similar                                                                                               |
| Research                                     | division in the Center for Drug Evaluation and Research (CDER), Food and Drug Administration, 5901-B Ammendale Rd.,                                      |
| Beltsville, MD                               | (CDER), Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266 or the Food and Drug Administration, Center                        |
| Research                                     | division in the Center for Drug Evaluation and Research (CDER), Food and Drug Administration, 5901-B Ammendale Rd.,                                      |
| Rm                                           | 71,  Rm .                                                                                                                                                |
| G112                                         | G112 , Silver Spring, MD 20993-0002.                                                                                                                     |
| Exemption                                    | Exemption requests should be submitted in writing to the                                                                                                 |
| Code                                         | Code  imprint required.                                                                                                                                  |
| Homeopathic                                  | Homeopathic drug products are required only to bear an                                                                                                   |
| Bulk                                         | Bulk drug substance, as referenced in sections 503A(b)(1)(A) and                                                                                         |
| United States                                | neither imported nor offered for import into the United States .                                                                                         |
| Domestic                                     | Domestic for purposes of registration and listing under this                                                                                             |
| United States                                | establishment within any State or Territory of the United States , the District of Columbia, or the Commonwealth                                         |
| Columbia                                     | Territory of the United States, the District of Columbia , or the Commonwealth of Puerto Rico.                                                           |
| Puerto Rico                                  | the District of Columbia, or the Commonwealth of Puerto Rico .                                                                                           |
| Drug                                         | Drug , for the purposes of registration and listing                                                                                                      |
| Establishment                                | Establishment means a place of business under one management                                                                                             |
| United States                                | is imported or offered for import into the United States .                                                                                               |
| United States                                | is imported or offered for import into the United States .                                                                                               |
| United States                                | purposes of this part, a person in the United States that is an owner, consignee, or recipient, at                                                       |
| United States                                | purposes of this part, a person in the United States that is an owner, consignee, or recipient, at                                                       |
| Manufacture                                  | Manufacture means each step in the manufacture, preparation, propagation,                                                                                |
| Manufacture                                  | Manufacture includes the making by chemical, physical, biological, or                                                                                    |
| Manufacture                                  | Manufacture includes manipulation, sampling, testing, or control procedures applied                                                                      |
| Material                                     | Material change means any change in any drug listing                                                                                                     |
| United States                                | a drug from a foreign country to the United States .                                                                                                     |
| United States                                | includes persons who send a drug to the United States by international mail or other private delivery service,                                           |
| Relabel                                      | Relabel means to change the existing label or labels                                                                                                     |
| Salvage                                      | Salvage means the act of segregating out those finished                                                                                                  |
| Salvager                                     | Salvager means a person who owns or operates an                                                                                                          |
| Bulk                                         | Bulk  drug substance.                                                                                                                                    |
| Bulk                                         | Bulk drug substance, as referenced in sections 503A(b)(1)(A) and                                                                                         |
| Establishment                                | Establishment registration information helps FDA identify who is manufacturing,                                                                          |
| Agriculture                                  | and unrevoked license issued by the Secretary of Agriculture under the animal virus-serum-toxin law of March 4,                                          |
| United States                                | are imported or offered for import into the United States must comply with the establishment registration and listing                                    |
| U.S                                          | trade zone and are re-exported without having entered U.S . commerce, or (2) Their drugs are imported                                                    |
| United States                                | is imported or offered for import into the United States .                                                                                               |
| United States                                | is imported or offered for import into the United States .                                                                                               |
| United States                                | email address must be provided for: (1) The United States agent, as provided in &#167;&#8201;207.69(b); (2) Each importer                                |
| United States                                | email address must be provided for: (1) The United States agent, as provided in &#167;&#8201;207.69(b); (2) Each importer                                |
| United States                                | email address must be provided for: (1) The United States agent, as provided in &#167;&#8201;207.69(b); (2) Each importer                                |
| United States                                | email address of the official contact or the United States  agent.                                                                                       |
| United States                                | A registrant, official contact, or  United States agent may notify FDA about a change of                                                                 |
| United States                                | A registrant, official contact, or  United States agent may notify FDA about a change of                                                                 |
| United States                                | A registrant, official contact, or  United States agent may notify FDA about a change of                                                                 |
| U.S                                          | (6) The dosage form; (7) The drug's approved U.S . application number, if any; (8) The drug                                                              |
| English                                      | (b)  English  language.                                                                                                                                  |
| Drug                                         | Drug establishment registration and drug listing information must be                                                                                     |
| English                                      | drug listing information must be provided in the English  language.                                                                                      |
| English                                      | must be provided at a minimum in the English  language.                                                                                                  |
| English                                      | submitted in that language along with an accurate English  translation.                                                                                  |
| U.S                                          | is not reasonable for the registrant and a U.S . telephone number and mailing address where FDA                                                          |
| U.S                                          | waiver requests must be sent to: SPL Coordinator, U.S .                                                                                                  |
| Food                                         | Food  and Drug Administration, 10903 New Hampshire Ave., Bldg.                                                                                           |
| United States                                | the requirements for an official contact and a United States  agent?                                                                                     |
| United States                                | (b)  United States  agent.                                                                                                                               |
| United States                                | subject to this part must designate a single United States  agent.                                                                                       |
| United States                                | The  United States agent must reside or maintain a place of                                                                                              |
| United States                                | The  United States agent must reside or maintain a place of                                                                                              |
| United States                                | The  United States agent must reside or maintain a place of                                                                                              |
| United States                                | The  United States agent is responsible for: (1) Reviewing, disseminating, routing,                                                                      |
| United States                                | The  United States agent is responsible for: (1) Reviewing, disseminating, routing,                                                                      |
| United States                                | The  United States agent is responsible for: (1) Reviewing, disseminating, routing,                                                                      |
| United States                                | FDA's providing information and/or documents to the  United States agent is equivalent to providing the same information                                 |
| Failure                                      | Failure  to comply with &#167;&#8201;207.37 may also constitute misbranding.                                                                             |
| Scope                                        | Scope  and purpose.                                                                                                                                      |
| Serious                                      | (k)  Serious risk or serious adverse effect means an adverse                                                                                             |
| English                                      | (1) The Medication Guide shall be written in English , in nontechnical, understandable language, and shall not                                           |
| Food                                         | Food and Drug Administration&#8221; shall appear at the bottom                                                                                           |
| Scope                                        | Scope  and purpose.                                                                                                                                      |
| Authorized                                   | Authorized dispenser means an individual licensed, registered, or otherwise                                                                              |
| Pharmacy                                     | Pharmacy includes, but is not limited to, a retail,                                                                                                      |
| Side                                         | Side effects statement means the following verbatim statement: &#8220;Call                                                                               |
| Failure                                      | Failure to comply with any applicable regulation set forth                                                                                               |
| Scope                                        | Scope .                                                                                                                                                  |
| Personnel                                    | Personnel  responsibilities.                                                                                                                             |
| Design                                       | Design  and construction features.                                                                                                                       |
| Ventilation                                  | Ventilation , air filtration, air heating and cooling.                                                                                                   |
| Plumbing                                     | Plumbing .                                                                                                                                               |
| Potable                                      | Potable water shall meet the standards prescribed in the                                                                                                 |
| Sewage                                       | Sewage  and refuse.                                                                                                                                      |
| Sewage                                       | Sewage , trash, and other refuse in and from                                                                                                             |
| Adequate                                     | Adequate washing facilities shall be provided, including hot and                                                                                         |
| Sanitation                                   | Sanitation .                                                                                                                                             |
| Trash                                        | Trash and organic waste matter shall be held and                                                                                                         |
| Fungicide                                    | and used in accordance with the Federal Insecticide, Fungicide , and Rodenticide Act (7 U.S.C. 135).                                                     |
| Maintenance                                  | Maintenance .                                                                                                                                            |
| Equipment                                    | Equipment  design, size, and location.                                                                                                                   |
| Equipment                                    | Equipment used in the manufacture, processing, packing, or holding                                                                                       |
| Automatic                                    | Automatic , mechanical, and electronic equipment.                                                                                                        |
| Written                                      | Written records of those calibration checks and inspections shall                                                                                        |
| Input                                        | Input to and output from the computer or related                                                                                                         |
| Receipt                                      | Receipt and storage of untested components, drug product containers,                                                                                     |
| Specific                                     | Specific  identity tests, if they exist, shall be used.                                                                                                  |
| Drug                                         | Drug  product containers and closures.                                                                                                                   |
| Such                                         | Such  depyrogenation processes shall be validated.                                                                                                       |
| Portable                                     | Portable cryogenic medical gas containers that are not manufactured                                                                                      |
| Written                                      | Written  procedures; deviations.                                                                                                                         |
| Written                                      | Written production and control procedures shall include the following,                                                                                   |
| Calculation                                  | Calculation  of yield.                                                                                                                                   |
| Actual                                       | Actual yields and percentages of theoretical yield shall be                                                                                              |
| Examination                                  | Examination and testing of samples shall assure that the                                                                                                 |
| Such                                         | Such  deviation shall be justified and documented.                                                                                                       |
| Access                                       | Access to the storage area shall be limited to                                                                                                           |
| Such                                         | Such examination shall be performed by one person and                                                                                                    |
| Packaging                                    | Packaging  and labeling operations.                                                                                                                      |
| Request                                      | clearly identified on the envelope as a &#8220; Request for Exemption from the Tamper-Evident Packaging Rule.&#8221; The                                 |
| Drug                                         | Drug  product inspection.                                                                                                                                |
| Expiration                                   | Expiration  dating.                                                                                                                                      |
| New                                          | (g)  New drug products for investigational use are exempt from                                                                                           |
| Written                                      | Written procedures describing the warehousing of drug products shall                                                                                     |
| Distribution                                 | Distribution  procedures.                                                                                                                                |
| Written                                      | Written procedures shall be established, and followed, describing the                                                                                    |
| Laboratory                                   | Laboratory  controls shall include:                                                                                                                      |
| Such                                         | Such validation and documentation may be accomplished in accordance                                                                                      |
| Prior                                        | Prior to acceptance and use, reprocessed material must meet                                                                                              |
| Accelerated                                  | Accelerated studies, combined with basic stability information on the                                                                                    |
| Reserve                                      | Reserve  samples.                                                                                                                                        |
| Reserve                                      | Reserve samples of compressed medical gases need not be                                                                                                  |
| Laboratory                                   | Laboratory  animals.                                                                                                                                     |
| Penicillin                                   | Penicillin  contamination.                                                                                                                               |
| Such                                         | Such drug product shall not be marketed if detectable                                                                                                    |
| Drugs                                        | &#8216;Procedures for Detecting and Measuring Penicillin Contamination in Drugs ,&#8217; which is incorporated by reference.                             |
| Research and Testing                         | Copies are available from the Division of  Research and Testing (HFD-470), Center for Drug Evaluation and Research, Food                                 |
| Research                                     | Copies are available from the Division of  Research  and Testing (HFD-470), Center for Drug Evaluation and                                               |
| Written                                      | Written procedures shall be established and followed for such                                                                                            |
| Master                                       | Master  production and control records.                                                                                                                  |
| Batch                                        | Batch  production and control records.                                                                                                                   |
| Batch                                        | Batch production and control records shall be prepared for                                                                                               |
| Dates                                        | holding of the batch was accomplished, including: (1) Dates ; (2) Identity of individual major equipment and                                             |
| Laboratory                                   | Laboratory  records.                                                                                                                                     |
| United States Pharmacopeia                   | employed is in the current revision of the United States Pharmacopeia , National Formulary, AOAC INTERNATIONAL, Book of Methods,&#8201;1                 |
| Distribution                                 | Distribution  records.                                                                                                                                   |
| Distribution                                 | Distribution records shall contain the name and strength of                                                                                              |
| Written                                      | Written records involving a drug product shall be maintained                                                                                             |
| Drug                                         | Drug  product salvaging.                                                                                                                                 |
| Drug                                         | Drug products that have been subjected to improper storage                                                                                               |
| Organoleptic                                 | Organoleptic examinations shall be acceptable only as supplemental evidence                                                                              |
| Acceptance                                   | Acceptance criteria means numerical limits, ranges, or other criteria                                                                                    |
| Batch                                        | Batch means a specific quantity of PET drug intended                                                                                                     |
| Batch                                        | Batch production and control record means a unique record                                                                                                |
| Final                                        | Final release means the authoritative decision by a responsible                                                                                          |
| Inactive                                     | Inactive ingredient means any intended component of the PET                                                                                              |
| Lot                                          | Lot means a batch, or a specifically identified portion                                                                                                  |
| Lot                                          | Lot number, control number, or batch number means any                                                                                                    |
| Master                                       | Master production and control record means a compilation of                                                                                              |
| Material                                     | Material release means the authoritative decision by a responsible                                                                                       |
| Quality                                      | Quality assurance means a system for ensuring the quality                                                                                                |
| Strength                                     | Strength means the concentration of the active pharmaceutical ingredient                                                                                 |
| Verification                                 | Verification means confirmation that an established method, process, or                                                                                  |
| United States Pharmacopeia                   | of the  United States Pharmacopeia  (USP) National Formulary (NF) (USP 32/NF 27) (2009).                                                                 |
| United States Pharmacopeial Convention, Inc  | You may obtain a copy from the  United States Pharmacopeial Convention, Inc ., 12601 Twinbrook Pkwy., Rockville, MD 20852, Geeta                         |
| Rockville, MD                                | United States Pharmacopeial Convention, Inc., 12601 Twinbrook Pkwy., Rockville, MD 20852, Geeta M. Tirumalai, 301-816-8352, e-mail: gt@usp.org, Internet |
| Equipment                                    | Equipment must be constructed and maintained so that surfaces                                                                                            |
| Batch                                        | (c)  Batch  production and control records.                                                                                                              |
| Process                                      | Process controls must include control of in-process materials to                                                                                         |
| Process                                      | Process  verification activities and results must be documented.                                                                                         |
| Documentation                                | Documentation must include the date and signature of the                                                                                                 |
| Laboratory                                   | Laboratory analytical methods must be suitable for their intended                                                                                        |
| Sterility                                    | Sterility testing need not be completed before final release                                                                                             |
| Drug                                         | Drug products withdrawn or removed from the market for                                                                                                   |
| Training                                     | Training and experience leads to proper use of equipment,                                                                                                |
| Equipment                                    | Equipment .                                                                                                                                              |
| Such                                         | Such equipment permits production of feeds of uniform quality,                                                                                           |
| Manufacturing                                | Manufacturing , storage, or handling of nonfeed and feed                                                                                                 |
| Laboratory                                   | Laboratory  controls.                                                                                                                                    |
| Equipment                                    | Equipment  cleanout procedures.                                                                                                                          |
| Such                                         | Such labeling may consist of a placard or other                                                                                                          |
| Master                                       | Master  record file and production records.                                                                                                              |
| Distribution                                 | Distribution  records.                                                                                                                                   |
| Areas                                        | Areas shall include access for routine maintenance and cleaning                                                                                          |
| Equipment                                    | Equipment .                                                                                                                                              |
| Work                                         | Work  and storage areas.                                                                                                                                 |
| Work                                         | Work areas and equipment used for the production or                                                                                                      |
| Adequate                                     | Adequate procedures shall be established and maintained for the                                                                                          |
| Laboratory                                   | Laboratory  assays.                                                                                                                                      |
| Equipment                                    | Equipment  cleanout procedures.                                                                                                                          |
| Adequate                                     | Adequate procedures shall be established and used for all                                                                                                |
| Labels                                       | Labels shall be received, handled, and stored in a                                                                                                       |
| Formula                                      | Formula , production, and distribution records.                                                                                                          |
| Equipment                                    | Equipment .                                                                                                                                              |
| Equipment                                    | Equipment used for the manufacture, processing, packaging, bulk shipment,                                                                                |
| Appropriate                                  | Appropriate receipt and inventory records shall be maintained for                                                                                        |
| Laboratory                                   | Laboratory  controls.                                                                                                                                    |
| Laboratory                                   | Laboratory controls shall include the establishment of adequate specifications                                                                           |
| Laboratory                                   | Laboratory controls shall include: (a) The establishment of master                                                                                       |
| Suitable                                     | Suitable expiration dates shall appear on the labels of                                                                                                  |
| Packaging                                    | Packaging  and labeling.                                                                                                                                 |
| Distribution                                 | Distribution  records.                                                                                                                                   |
| Food                                         | The Commissioner of  Food and Drugs finds that the administration of such                                                                                |
| Food                                         | In particular, the Commissioner of  Food and Drugs finds that neither the consensus of                                                                   |
| Stramonium                                   | Stramonium preparations labeled with directions for use in self-medication                                                                               |
| Misuse                                       | Misuse of stramonium preparations can cause serious toxic effects                                                                                        |
| Food                                         | the basis of this information, the Commissioner of Food and Drugs has concluded that such articles have                                                  |
| Amyl                                         | Amyl nitrite inhalant as a prescription drug for human                                                                                                   |
| Food                                         | 25, 1967 (32 FR 12404), the Commissioner of Food and Drugs received reports of the abuse of                                                              |
| Food                                         | it is the opinion of the Commissioner of Food  and Drugs, concurred in by the                                                                            |
| Amphetamine                                  | Amphetamine  and methamphetamine inhalers regarded as prescription drugs.                                                                                |
| Food                                         | physicians, parents, and others as well as from Food and Drug Administration investigations, it is evident that                                          |
| Amphetamine                                  | Amphetamine tablets and amphetamine inhalers have been restricted to                                                                                     |
| Drug                                         | is the considered opinion of the Food and Drug Administration that, in order to adequately protect the                                                   |
| Experience                                   | Experience with these cases shows that such use of                                                                                                       |
| Severe                                       | Severe injury may result from use internally or as                                                                                                       |
| Avoid                                        | Avoid  contact with mucous membranes.&#8221;                                                                                                             |
| United States Pharmacopeia                   | of the Anti-anemia Preparations Advisory Board of the United States Pharmacopeia is concerned with the status of the treatment                           |
| United States                                | The Sixteenth Revision of the Pharmacopeia of the United States , which became official on October 1, 1960,                                              |
| Food                                         | pertinent information from other sources, the Commissioner of Food and Drugs finds it is the consensus of                                                |
| Parenteral                                   | Parenteral cyanocobalamin preparations have not been and are not                                                                                         |
| Pernicious                                   | Pernicious anemia is a disease that is associated, among                                                                                                 |
| Hexachlorophene                              | Hexachlorophene , as a component of drug and cosmetic                                                                                                    |
| Human                                        | Human toxicity reports include data on symptomatology, blood and                                                                                         |
| Such                                         | Such use of hexachlorophene shall be limited to situations                                                                                               |
| Hexachlorophene                              | Hexachlorophene may be used as a preservative in cosmetic                                                                                                |
| Such                                         | Such use of hexachlorophene shall be limited to situations                                                                                               |
| Drugs                                        | Drugs ; statement of required warning.                                                                                                                   |
| Spanish                                      | the patient for whom it was prescribed.&#8221; The Spanish version of this is: &#8220;Precaucion: La ley Federal                                         |
| Food                                         | (a) Section 508 of the Federal  Food , Drug, and Cosmetic Act (added by the                                                                              |
| United States Pharmacopeia                   | organization sponsored by the American Medical Association, the United States Pharmacopeia , and the American Pharmaceutical Association, and has        |
| U.S. Pharmacopeial Convention, Inc           | Copies are available from:  U.S. Pharmacopeial Convention, Inc ., 12601 Twinbrook Parkway, Rockville, MD 20852, or                                       |
| Rockville, MD                                | from: U.S. Pharmacopeial Convention, Inc., 12601 Twinbrook Parkway, Rockville, MD 20852, or are available for inspection at the                          |
| Prior                                        | Prior use of a name in the medical literature                                                                                                            |
| U.S                                          | (f) A cumulative list of  U.S . adopted names selected and released since June                                                                           |
| U.S. Pharmacopeial Convention, Inc           | June 15, 1961, is published yearly by the U.S. Pharmacopeial Convention, Inc ., in USAN and the USP Dictionary of                                        |
| U.S. Pharmacopeial Convention, Inc           | Copies may be purchased from the  U.S. Pharmacopeial Convention, Inc ., 12601 Twinbrook Parkway, Rockville, MD 20852.                                    |
| Rockville, MD                                | the U.S. Pharmacopeial Convention, Inc., 12601 Twinbrook Parkway, Rockville, MD  20852.                                                                  |
| Drugs                                        | Drugs ; compendial name.                                                                                                                                 |
| Reminder                                     | Reminder advertisements are those which call attention to the                                                                                            |
| Reminder                                     | Reminder advertisements, other than those solely intended to convey                                                                                      |
| Reminder                                     | Reminder advertisements which are intended to provide consumers with                                                                                     |
| Reminder                                     | Reminder advertisements, other than those subject to the requirements                                                                                    |
| Untrue                                       | Untrue or misleading information in any part of the                                                                                                      |
| True                                         | (5) &#8220; True  statement&#8221; of information.                                                                                                       |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-----------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1913-03-04 | (h) Any manufacturer, repacker, relabeler, or salvager of a virus, serum, toxin, or analogous product intended for the treatment of domestic animals who holds an unsuspended and unrevoked license issued by the Secretary of Agriculture under the animal virus-serum-toxin law of March 4, 1913 (37 Stat.                                                                                                                                                                                                                                                                                                                                                                      |
| 2018-10-01 | (1) The first review and update must occur during the period beginning on October 1 and ending December 31 of the year of initial registration, if the initial registration occurs prior to October 1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 2018-12-31 | (1) The first review and update must occur during the period beginning on October 1 and ending December 31 of the year of initial registration, if the initial registration occurs prior to October 1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 2018-10-01 | (1) The first review and update must occur during the period beginning on October 1 and ending December 31 of the year of initial registration, if the initial registration occurs prior to October 1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 2018-10-01 | Subsequent reviews and updates must occur annually, during the period beginning on October 1 and ending December 31 of each calendar year.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 2018-12-31 | Subsequent reviews and updates must occur annually, during the period beginning on October 1 and ending December 31 of each calendar year.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 2001-06-04 | (2) The following combinations of labeler code, product code and package code character lengths are permissible:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |                       (i) If a labeler code is either 5 or 6 digits in length, it may be combined with:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |                       (A) A product code consisting of 4 digits and a package code consisting of 1 digit for a total NDC length of 10 or 11 digits (5-4-1 or 6-4-1), or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |                       (B) A product code consisting of 3 digits and a package code consisting of 2 digits for a total NDC length of 10 or 11 digits (5-3-2 or 6-3-2).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 2002-06-03 | (2) The following combinations of labeler code, product code and package code character lengths are permissible:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |                       (i) If a labeler code is either 5 or 6 digits in length, it may be combined with:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |                       (A) A product code consisting of 4 digits and a package code consisting of 1 digit for a total NDC length of 10 or 11 digits (5-4-1 or 6-4-1), or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |                       (B) A product code consisting of 3 digits and a package code consisting of 2 digits for a total NDC length of 10 or 11 digits (5-3-2 or 6-3-2).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 2018-06-01 | (b) Registrants must review and update their drug listing information each June and December.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 2037-05-01 | Failure to comply with &#167;&#8201;207.37 may also constitute misbranding.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1978-09-29 | (c) Pending consideration of a proposed exemption, published in the Federal Register of September 29, 1978, the requirements in this part shall not be enforced for OTC drug products if the products and all their ingredients are ordinarily marketed and consumed as human foods, and which products may also fall within the legal definition of drugs by virtue of their intended use.                                                                                                                                                                                                                                                                                       |
| 1978-09-29 | (h) Pending consideration of a proposed exemption, published in the Federal Register of September 29, 1978, the requirements in this section shall not be enforced for human OTC drug products if their labeling does not bear dosage limitations and they are stable for at least 3 years as supported by appropriate stability data.                                                                                                                                                                                                                                                                                                                                            |
| 2018-03-01 | (c) For homeopathic drug products, the requirements of this section are as follows:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |                       (1) There shall be a written assessment of stability based at least on testing or examination of the drug product for compatibility of the ingredients, and based on marketing experience with the drug product to indicate that there is no degradation of the product for the normal or expected period of use.                                                                                                                                                                                                                                                                                                                                           |
| 2009-05-01 | For investigational PET drugs for human use produced under an investigational new drug application in accordance with part 312 of this chapter, and PET drugs produced with the approval of a Radioactive Drug Research Committee in accordance with part 361 of this chapter, the requirement under the act to follow current good manufacturing practice is met by complying with the regulations in this part or by producing PET drugs in accordance with Chapter 823, &#8220;Radiopharmaceuticals for Positron Emission Tomography&#8212;Compounding,&#8221; May 1, 2009, pp.                                                                                                |
| 1967-08-25 | As a result of a proposed policy statement published August 25, 1967 (32 FR 12404), the Commissioner of Food and Drugs received reports of the abuse of this drug by those who do not require it for medical purposes.                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 1969-07-01 | (b) Therefore, amyl nitrite inhalant will be regarded as misbranded unless the labeling on or within the package from which the drug is to be dispensed bears adequate information for its safe and effective use by physicians, in accordance with &#167;&#8201;201.100(c) of this chapter, and its label bears the statement &#8220;Rx only.&#8221;                                                                                                                                                                                                                                                                                                                             |
|            |                       (c) Regulatory proceedings may be initiated with regard to the interstate shipment of amyl nitrite inhalant that is labeled, advertised, or dispensed contrary to this statement of policy if such act occurs after July 1, 1969.                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 1960-10-01 | It clearly presents the following facts:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |                       (1) The Sixteenth Revision of the Pharmacopeia of the United States, which became official on October 1, 1960, does not include preparations intended for the treatment of pernicious anemia by oral administration.                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 1972-04-04 | A notice published in the Federal Register of April 4, 1972 (37 FR 6775), invited data on OTC antimicrobial ingredients, including hexachlorophene, for review by an OTC Drug Advisory Review Panel to be convened under the procedures set forth in the Federal Register of May 11, 1972 (37 FR 9464).                                                                                                                                                                                                                                                                                                                                                                           |
| 1972-05-11 | A notice published in the Federal Register of April 4, 1972 (37 FR 6775), invited data on OTC antimicrobial ingredients, including hexachlorophene, for review by an OTC Drug Advisory Review Panel to be convened under the procedures set forth in the Federal Register of May 11, 1972 (37 FR 9464).                                                                                                                                                                                                                                                                                                                                                                           |
| 1978-01-31 | (4) Marketing of products for the indications listed in paragraph (c)(3) of this section may be continued without an approved new drug application (or required supplement thereto) either until a notice of opportunity for hearing is issued on a proposal by the Director of the Center for Drug Evaluation and Research to refuse to approve such new drug application (or required supplement) or until January 31, 1978, whichever comes first, if all the following conditions were met after September 27, 1972:                                                                                                                                                          |
|            |                       (i) The product is labeled with the statement &#8220;Rx only&#8221; and adequate information for safe and effective use as set forth in paragraph (c)(3) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 1972-09-27 | (4) Marketing of products for the indications listed in paragraph (c)(3) of this section may be continued without an approved new drug application (or required supplement thereto) either until a notice of opportunity for hearing is issued on a proposal by the Director of the Center for Drug Evaluation and Research to refuse to approve such new drug application (or required supplement) or until January 31, 1978, whichever comes first, if all the following conditions were met after September 27, 1972:                                                                                                                                                          |
|            |                       (i) The product is labeled with the statement &#8220;Rx only&#8221; and adequate information for safe and effective use as set forth in paragraph (c)(3) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 1972-10-27 | (ii) Within 30 days, or by (10-27-72) the holder of an approved new drug application submits a supplement to provide for the revised label and full disclosure labeling.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 1972-10-27 | (iii) Within 30 days, or by (10-27-72) the holder of an approved new drug application submits a supplement to provide for a revised formulation where appropriate to comply with this order.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 1972-12-26 | (iv) Within 90 days, or by (12-26-72) the holder of an approved new drug application submits a supplement containing blood level data obtained from use of the drug as recommended, unless such information is a part of the new drug application file.                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 1972-12-26 | (v) Within 90 days, or by (12-26-72), the manufacturer or distributor of such a drug for which a new drug approval is not in effect submits a new drug application in accord with &#167;&#8201;314.50 of the new drug regulations (21 CFR 314.50), including blood level data obtained from use of the drug as recommended.                                                                                                                                                                                                                                                                                                                                                       |
| 1964-01-01 | Adopted Names Council is a private organization sponsored by the American Medical Association, the United States Pharmacopeia, and the American Pharmaceutical Association, and has been engaged in the assignment of names to drugs since January 1964.                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 1961-06-15 | (f) A cumulative list of U.S. adopted names selected and released since June 15, 1961, is published yearly by the U.S. Pharmacopeial Convention, Inc., in USAN and the USP Dictionary of Drug Names.                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 1962-10-10 | (i)(a) An advertisement for a prescription drug covered by a new-drug application approved pursuant to section 505 of the act after October 10, 1962, or a prescription drug covered by a new animal drug application approved pursuant to section 512 of the act after August 1, 1969, or any approved supplement thereto, or for a prescription drug listed in the index pursuant to section 572 of the act, or any granted modification thereto, shall not recommend or suggest any use that is not in the labeling accepted in such approved new-drug application or supplement, new animal drug application or supplement, or new animal drug index listing or modification. |
| 1969-08-01 | (i)(a) An advertisement for a prescription drug covered by a new-drug application approved pursuant to section 505 of the act after October 10, 1962, or a prescription drug covered by a new animal drug application approved pursuant to section 512 of the act after August 1, 1969, or any approved supplement thereto, or for a prescription drug listed in the index pursuant to section 572 of the act, or any granted modification thereto, shall not recommend or suggest any use that is not in the labeling accepted in such approved new-drug application or supplement, new animal drug application or supplement, or new animal drug index listing or modification. |
| 1962-10-10 | (b) If a prescription drug was covered by a new-drug application or a supplement thereto that became effective prior to October 10, 1962, an advertisement may recommend or suggest:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |             (1) Uses contained in the labeling accepted in such new-drug application and any effective, approved, or permitted supplement thereto.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 1962-10-09 | (2) Additional uses contained in labeling in commercial use on October 9, 1962, to the extent that such uses did not cause the drug to be an unapproved &#8220;new drug&#8221; as &#8220;new drug&#8221; was defined in section 201(p) of the act as then in force, and to the extent that such uses would be permitted were the drug subject to paragraph (e)(4)(iii) of this section.                                                                                                                                                                                                                                                                                           |


